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ABSTRACT
Statistical Methods for Bayesian Adaptive Early-Phase Clinical Trial Designs
by
Jin Zhang
Chair: Thomas M. Braun
This dissertation develops new methods for unaddressed issues in the design of Bayesian
adaptive Phase I and Phase I/II oncology clinical trials, which are trials that seek to
identify the optimal dose and/or schedule of a new cytotoxic agent in a small group
of patients either based on dose-limiting toxicity (DLT) alone or both toxicity and
efficacy.
Our first project focuses on methods to calibrate the prior variance assumed for
the parameter in the Continual Reassessment Method (CRM). We propose three sys-
tematic approaches to adaptively calibrate the prior variance continually throughout
the trial and compare those approaches to existing methods that calibrate the vari-
ance only at the beginning of a trial. Computer simulations show that our approaches
have the ability to perform better than the existing methods under various scenarios.
In our second project, we extend the traditional Phase I dose-schedule-finding de-
sign that only optimizes dose and schedule among patients by adaptively re-evaluating
and, if necessary, varying the intra-patient dose-schedule assignment as the study
proceeds. Our design is based on a Bayesian non-mixture cure rate model that in-
corporates multiple administrations each patient receives with the per-administration
xii
dose included as a covariate. Simulations indicate that our design identifies correct
dose and schedule combinations as well as the traditional method that does not allow
for intra-patient doses-schedule reassignments, but with a larger number of patients
assigned to those combinations. The method is illustrated by application to a bone
marrow transplantation trial for acute myelogenous leukemia (AML).
In our third project, we generalize our method in the second project by jointly
modeling toxicity and efficacy as time-to-event outcomes in a Phase I/II clinical trial.
We adopt a non-mixture cure rate model for the marginal distributions. A copula
is then assumed to obtain a bivariate time-to-event distribution. To ensure an eth-
ical trial, dose-schedule regimes are selected for successive patient cohorts based on
the proposed safety and efficacy acceptability criteria at each decision-making time.
Through simulations we show that the proposed design has a high probability of





Early-phase clinical trials are first-in-human studies for a new agent. This thesis
focuses on the development of novel statistical methods for Bayesian adaptive dose-
and/or schedule-finding designs in Phase I and Phase I/II oncology trials.
Anti-cancer drugs are naturally toxic in order to kill cancer cells or suppress their
growth. Thus, the study subjects in oncology trials are cancer patients, instead of
healthy volunteers that might be used in other therapeutic areas. In oncology trials,
especially for cytotoxic drugs, the general belief of oncologists is that the more toxic a
regimen (a single drug, combined drugs or a dose-schedule combination) is, the more
efficacious it will be. In addition, it is often reasonable to assume that the higher
the dose is, the more toxic the regimen should be. In a typical early-phase oncology
trial, the clinician suggests several doses and/or schedules regimes for investigation
and tries to identify the optimal regimen. Hence, the number of regimes under study
is actually finite rather than lying along continuum.
In Phase I oncology trials, the investigators are interested in determining a treat-
ment regimen that is not only safe but also likely to be efficacious in a small group of
patients, typically ranging from 15-40 patients. A reasonable approach is to specify a
target toxicity rate η that should be sufficiently low to indicate safety and sufficiently
1
high to indicate efficacy, where η usually falls in the interval [0.2, 0.4]. Toxicity here
does not include all types of adverse events but is a dose-limiting toxicity (DLT),
which, even though varying among trials , often includes Grade 3 or higher toxicity
according to the National Cancer Institute. The dose with dose-limiting toxicity rate
closest to η is usually defined as the maximum tolerated dose (MTD), although a
penalty could be imposed to select a lower dose for over-dose control and trial safety.
One of the main goals of Phase I clinical trials in oncology is to establish the MTD
that will be examined further in a Phase II trial for efficacy.
A limitation of a typical Phase I trial design is that efficacy is ignored and dose
finding is based on toxicity alone, although efficacy information is still collected.
Ignoring efficacy outcomes might result in an inefficient design that tends to target
a suboptimal regimen or requires a larger sample size. One obvious reason is that
the MTD might not be estimated in a reliable way in a Phase I trial due to the
small sample size. Second, for cytostatic agents, efficacy effect may not necessarily
increase with the dose. Therefore, it might be a better strategy to incorporate both
toxicity and efficacy in a seamless phase I/II design. Third, for trials that aim to
identify optimal dose combinations or dose-schedule combinations, there would be no
obvious ordering in terms of toxicity or efficacy for the combinations in the dose-dose
or dose-schedule matrix. It is very likely that two regimes could be very similar in
the DLT rate but differs substantially in response rates. Hence, it would be desirable
to consider both toxicity and efficacy for dose and/or schedule finding, necessitating
a seamless Phase I/II trial design. In general, the main goal of a Phase I/II clinical
trial is to identify a treatment regimen that is both safe and efficacious by imposing
some conditions on the toxicity and response rate when selecting the best regimen
for a new cohort of patients.
Since anti-cancer agents are quite toxic, a Phase I or Phase I/II trial should (1)
minimize the number of patients treated at sub-optimal regimes, including those
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overly toxic regimes and those with unacceptably low toxicity rates or low response
rates; (2) stop a Phase I trial early if it is very likely that no acceptably safe regimen
and stop a Phase I/II trial early if there is sufficient evidence that no regimen under
investigation is both safe and efficacious. To meet the above ethical constraints,
patients are rarely randomized to all the investigational treatment regimes. Instead,
patients are enrolled in cohorts and the assignment for the next cohort is adaptively
determined based on the observed accumulating data from the enrolled patients. This
procedure will be repeated until the maximum number of patients is reached or the
trial is stopped early.
The focus of this thesis is on model-based methods and the optimal regimen will
be determined based on the proposed dose-toxicity and/or dose-response model. We
adopt a Bayesian approach because early-phase trials have relatively small sample
sizes and a Bayesian approach is useful for the decisions to make at each interim anal-
ysis. For example, the Bayesian Continual Reassessment Method (CRM) in Phase I
dose-finding trials assumes a single-parameter dose-toxicity model, updates the model
parameter whenever a new cohort is enrolled, and selects the current MTD, which
is defined to the one with estimated DLT rate close to the target η, to assign to the
next cohort (o’Quigley, Pepe, and Fisher 1990).
Due to the ethical constraints mentioned above, it would be ideal that we assign
most of our patients at or around the optimal treatment regimen. As a result, the trial
is typically severely unbalanced, which might cause problems in estimating the DLT
or response rates of those regimes that very few patients are assigned to. However,
since the main goal is to identify the optimal regimen instead of finding a good model,
minimizing the bias/variance of the model parameter estimate is not quite relevant.
Instead, we are more interested in the local model fit for the dose-toxicity/dose-
response curve around the optimal regimen. In light of the above design features
and the small sample size in an early phase trial, a parsimonious model is usually
3
preferred to a complex model. For example, the CRM assumes a single-parameter
model that has been shown to perform well in numerous simulation studies and a two-
parameter model does not improve the operating characteristics(Shu and O’Quigley
2008; Paoletti and Kramar 2009).
1.2 Motivation and Significance
We develop methods for three unaddressed issues in Bayesian adaptive Phase I
and Phase I/II trial designs. The details will be discussed in the ensuing chapters. In
Chapter II, we focus on methods to adaptively calibrate the prior variance assumed
for the parameter in the Phase I Bayesian CRM in order to improve its operating
characteristics. Due to the small sample size in a Phase I study, the CRM can be
sensitive to the amount of the prior variance. Although methods have emerged to
adaptively select skeletons and to calibrate the prior variance only at the beginning
of a trial, there has not been any approach developed to adaptively calibrate the prior
variance throughout a trial. We propose three systematic approaches to adaptively
calibrate the variance of the prior distribution during a trial in the CRM and compare
those approaches via simulation to existing methods that calibrate the variance only
at the beginning of a trial (Zhang, Braun, and Taylor 2012).
In Chapter III, we develop methods for dose-schedule-finding designs in which we
generalize the methods of Liu and Braun (2009) to simultaneously optimize the dose
and schedule assigned to each patient. A second limitation of existing model-based
adaptive Phase I designs is that they only determine the assignment for the next
patient or group of patients by using the most recent model estimates. What these
designs fail to do is to re-examine the assignments of patients who are still receiving
treatment and may benefit from a change to their assignment, such as a higher dose
at the next administration or increasing the number of planned administrations at
the current dose. It is important to introduce intra-patient dose and/or schedule
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reassignment when necessary, especially for the patients enrolled early in a trial since
they are more likely to receive a suboptimal dose or schedule. Although the model of
Braun et al. (2007) could allow the possibility that the patients planned dose for each
administration to be changed, both the benefit of intra-patient dose change and how
to reassign intra-patient dose and/or schedules are areas that have not been studied.
The second contribution of our work is to adaptively optimize the dose and schedule
assignments both among patients and within patients.
In Chapter IV, we generalize the method of Phase I dose-schedule-finding in Chap-
ter III to allow for both toxicity and efficacy outcomes by modeling times to toxicity
and efficacy outcomes jointly. There are several challenges for designing such a trial.
First, the ordering information in terms of either toxicity or response rates is not
completely known for two dose-schedule regimes, which excludes the use of 3+3 and
other traditional escalation/de-escalation methods that rely on the ordering informa-
tion. Secondly, patient responses usually take a relatively long time to assess and
an efficient design should be able to incorporate incomplete follow-up for the out-
comes. However, most of current Phase I/II designs require complete follow-up for
each enrolled patience because they model binary outcomes instead of time-to-event
outcomes. As a result, the total duration of a trial might be overly long. Third,
the definition of the schedule can vary between studies. A typical schedule can be
either a nested schedule or a non-nested schedule. However, there has not been any
systematic approach to handle both of them. Lastly, intra-patient dose modification
is common in practice but most of current Phase I/II designs fail to accommodate
intra-patient dose variation. In order to address all the issues above, we adopt the
marginal survival functions using the non-mixture cure rate models that incorporate
the cumulative effect due to multiple administration with each per-administration
dose as a covariate. A copula is then assumed to obtain a bivariate time-to-event
distribution. To ensure an ethical trial, adaptive safety and efficacy acceptability
5
conditions are imposed on the dose-schedule regimes.
In Chapter V, we present a brief summary of our proposed work, and discuss
future research areas that can be explored further based on our current work.
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CHAPTER II
Adaptive Prior Variance Calibration in the
Bayesian Continual Reassessment Method
2.1 Introduction
Phase I clinical trials are studies of human subjects aimed at estimating the
maximum-tolerated dose (MTD) with the sample size typically in the range of 20-40
subjects. The MTD is the dose at which the probability of having a dose-limiting
toxicity (DLT) is near a predefined target 0 < η < 1. Since the dose identified as
the MTD will be further investigated for efficacy in Phase II trials, it is important to
obtain an accurate estimate for the MTD. Due to the severity of most DLTs, patient
safety dictates that the study begins at low doses and escalates doses as patients are
accrued so that exposure of patients to doses above the MTD is minimized. However,
escalation of doses should also occur as quickly as possible as lower doses are also
expected to be ineffective for treating or preventing recurrence of cancer.
A vast amount of methodology exists for the design of Phase I trials. The 3 +
3 design is the standard algorithmic design using cohorts of three patients. While
algorithmic designs are simple to understand and implement, their resulting MTD
estimates have large bias and variance. Also, many subjects are likely to be treated
at doses below the MTD (Storer 1989; Rosenberger and Haines 2009).
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A preferred design would incorporate a parametric model for the association of
dose and probability of DLT. One popular model-based method is the Continual
Reassessment Method (CRM) which provides the MTD estimate from a fixed set
of dose levels using a one-parameter model for the dose-toxicity relationship. The
parameter estimate is updated every time a new subject or cohort completes its
follow-up either using Bayesian methods as proposed by O’Quigley, Pepe, and Fisher
(1990) or maximum likelihood methods as proposed by O’Quigley and Shen (1996).
In the Bayesian CRM, one must determine a priori DLT rates for each dose,
referred to as a skeleton, and the first subject is assigned to the dose whose skeleton
value is closest to η. Faries (1994), Korn et al. (1994) and Moller (1995) proposed
modifications to the original CRM to promote patient safety and slow dose escalation.
Specifically, the modified CRM suggests that the first patient be assigned to the lowest
dose, regardless of the skeleton, and that skipping of doses during dose escalation
should not be allowed. Numerous extensions to the CRM have been published since
the original CRM manuscript, including the time-to-event CRM (TITE-CRM) of
Cheung and Chappell (2000) to account for incomplete follow-up of patients and the
later generalization of Braun (2005) to adapt the TITE-CRM for early- and late-onset
DLTs. Yin and Yuan (2009) proposed the Bayesian Model Averaging CRM (BMA-
CRM) to allow for the incorporation of multiple skeletons, and Yuan and Yin (2011)
developed a hybrid design to combine rule-based methods and the CRM. Lee and
Cheung (2009; 2011) suggested a systematic but computationally intensive approach
to calibrate the skeleton through the use of indifference intervals.
The work of Lee and Cheung (2011) also proposed methods to determine the
value of the variance given to the prior distribution of the parameter in the dose-
toxicity model at the onset of the trial. In general Bayesian applications, a large, i.e.
vague, prior variance usually connotes a less-influential prior distribution, and Chevret
(1993) suggested using a vague prior variance with the Bayesian CRM, although the
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specific definition of vagueness is controversial. Lee and Cheung (2011) proposed
a least-informative prior variance, defined as that value of the prior variance that
results in all doses being a priori equally likely of being the MTD. The value of the
least-informative prior variance tends to be much smaller than what is traditionally
considered a vague prior variance.
It is also not appreciated that the level of vagueness of the prior variance is de-
pendent upon the values selected for the skeleton. The aggressive behavior of the
CRM in the case studies of Moller (1995) and Neuenschwander et al. (2008) can be
entirely explained by the dependence between the prior variance and the skeleton, so
that the prior variance used in each study was too small for the chosen skeleton. As
a specific example, O’Quigley et al. (1990) suggested using a standard exponential
distribution. Consider two skeletons for five dose levels: the original skeleton used by
O’Quigley et al. (1990) and a skeleton developed using the methods of Lee and Che-
ung (2011). Both skeletons specify the third dose as the MTD. The target probability
is 0.20, the true MTD is dose 6, the maximum number of enrolled patients is 25 and
the dose-response model is the hyperbolic model defined by O’Quigley et al. (1990).
From the results presented in Scenario 1 in Table 2.1, we see a notable difference in
the dose selected as the MTD under these two skeletons even though both use the
same prior distribution for the parameter. The prior distribution works well with
the second skeleton but may be too small for the first skeleton. If we increase the
prior variance by using a Gamma distribution with mean 1 and variance 4, the first
skeleton now gives results comparable to the second skeleton. Hence, the vagueness
of a prior variance heavily depends on the skeleton used.
For a specific skeleton used in a trial, the choice of the prior variance also depends
on the relative location of the true MTD and the MTD defined by the skeleton. If the
MTD specified by the skeleton is close to the true MTD, a small prior variance could
help find the correct MTD more efficiently. However, if the skeleton does not match
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Table 2.1: A simulation study comparing the impact of the prior variance and skeleton on the ability
to identify the MTD for the traditional CRM with a fixed prior variance. Numbers 1-6 in the first
row stand for doses 1 to 6. Other numbers in the table stand for the proportion of simulations that
select each dose as the MTD. Skeleton A denotes the original skeleton used by O’Quigley et al.:
{0.05, 0.10, 0.20, 0.30, 0.50,0.70} and Skeleton B denotes the skeleton used by Lee and Cheung:
{0.05, 0.11, 0.20, 0.31, 0.42, 0.53}. Numbers in bold indicate which dose is the MTD.
Scen Skeleton Prior 1 2 3 4 5 6
1 DLT rates: 0.00 0.00 0.03 0.05 0.11 0.22
A Exp(1) 0 0 0 6 65 29
B Exp(1) 0 0 0 4 36 60
A Gamma(1/4, 4) 0 0 0 3 36 61
2 DLT rates: 0.02 0.05 0.10 0.20 0.30 0.50
A Exp(1) 0 2 20 56 23 0
A Gamma(1/4, 4) 0 2 18 47 31 1
B Exp(1) 0 2 22 50 23 2
B Gamma(1/4, 4) 0 2 20 49 26 3
the truth well, then a larger prior variance is needed to help find the MTD. In Table
2.1, for the same Skeleton A, we find that a larger prior variance works better when
the true MTD is dose 6 and that a smaller prior variance works better when the true
MTD is dose 4. For both scenarios, the a priori MTD is dose 3. Again the vagueness
of a prior variance depends on the skeleton used. To achieve similar performance
with using Skeleton A and standard exponential distribution as the prior, one might
need to further reduce the prior variance used for Skeleton B. It seems that the CRM
using a constant prior variance could perform well in specific scenarios but might not
perform well in other scenarios, no matter which value is selected for the constant
prior variance.
The above motivating example indicates that the traditional methods to calibrate
the prior variance may not work well in many scenarios, since the traditional ap-
proaches try to find a prior variance based on the skeleton at the onset of a trial and
keep it constant during a trial but fail to take into account the relative location of the
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true MTD and a priori MTD for the specific scenario. However, the accumulating
data during a trial might provide us information regarding the relative distance be-
tween the truth and the skeleton. Hence, we consider the prior variance as a tuning
parameter that should be adaptively calibrated during the entire study to determine
whether or not the variance chosen at the beginning of the study should be modified.
We introduce three systematic approaches for adaptively calibrating the prior vari-
ance throughout a Phase I trial. In Section 2.2, we review the CRM and the work of
Lee and Cheung (2011). In Section 2.3, we present the details for our three variance
calibration approaches. In Section 2.4, we apply our methods to two hypothetical
settings and compare operating characteristics with current approaches. In Section
2.5, we conclude with some discussion.
2.2 Existing Methods
2.2.1 Continual Reassessment Method
Under the assumption that the probability of DLT increases monotonically with
dose, the CRM procedure updates the dose-response relationship throughout the trial
as new observations are available. Patients are assigned to the dose whose estimated
DLT rate is the closest to the target probability η, subject to possible restrictions.
Let J denote the number of doses examined and let N denote the number of subjects
enrolled by the end of the trial. For each dose j, j = 1, . . . , J , there is a skeleton value
pj, denoting the a priori DLT rate for dose j. The response yi of patient i is binary:
yi = 1, if there is DLT or yi = 0, if there is no DLT, i = 1, . . . , N . The CRM uses
a one-parameter model given by πi = ψ(xi; β), where β is some unknown parameter,
ψ is a monotonic function with the range [0, 1] and xi denotes the rescaled value of
the assigned dose for subject i. Here, we consider two commonly used models: (1) a
logistic model with intercept 3 given by ψ(xi; β) = 1/{1 + exp[−3 − exp(β)xi]} and
(2) a power model given by ψ(xi; β) = x
exp(β)
i . In both models, we place a normal
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prior on β with mean zero and variance σ2.
The rescaling of doses attempts to mirror the investigators’ prior assumptions and
provides a good fit over the skeleton probabilities for the dose levels under the study
(O’Quigley et al. 1990). Specifically, xi can take one of the rescaled values x
∗
j that
are determined from the equations
pj =
∫
ψ(x∗j ; β)g(β)dβ j = 1, . . . , J,
where g(β) is the prior distribution for β. In practice, this computation is replaced




Let Yn = {y1, . . . , yn} denote the observed DLT responses for subjects 1, . . . , n, 1 ≤
n ≤ N , after subject n has completed follow-up for DLT. Then the likelihood function




{ψ(xi; β)}yi {1− ψ(xi; β)}1−yi
By Bayes’ theorem, the posterior mean of the DLT rate at dose dj given the observed
data is given by










In practice, the plug-in estimator, ψ(x∗j ; β̃) where β̃ = E(β|Yn), is commonly used
to simplify the calculation for π̃j. Based on the updated posterior DLT rates π̃j,
j = 1, . . . , J , the recommended dose for the next patient is chosen as the one with a
DLT rate closest to the target η. So the next subject is assigned to dose level j such
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that
j = arg min
j∈(1,...,J)
|π̃j − η|. (2.2)
The CRM usually does not allow dose skipping during dose escalation. The trial
either progresses until the total number of subjects N is reached or is terminated if a
certain stopping rule is satisfied. The MTD is determined at the end of the trial by
simply selecting dose j according to (2.2) based upon YN .
In order to address the ethical concern of overdosing subjects, many authors have
developed stopping rules for dose-finding studies that halt a study if all doses under
study are too toxic, including Korn et al. (1994), O’Quigley (1992), and O’Quigley
and Reiner (1998). In our simulations presented in Section 2.4, we used a variant of
the stopping rule proposed by Thall and Russell (1998), in which the trial is stopped
and no dose is selected as the MTD once the posterior probability that the DLT rate
of the lowest dose is higher than the target probability is larger than a pre-specified
value.
2.2.2 Least Informative Prior Variance of Lee and Cheung (2011)
We first briefly review the concept of indifference intervals proposed by Cheung
and Chapell (2002) in the context of the CRM. The parameter space of β can be
divided into J intervals: I1 = [bl, b1), Ij = (bj, bj+1) for j = 1, . . . , J − 2 and IJ =
(bJ−1, bu), where b1, . . . , bJ−1 are solved from
ψ(x∗j ; bj) + ψ(x
∗
j+1; bj) = 2η, for j = 1, . . . , J − 1.
It is obvious that the CRM would assign dose j to the next subject if and only if the
estimate β̃ falls in the interval Ij, j = 1, . . . , J . Although β ∈ (−∞,∞), finite values
for bl and bu are used in practice to avoid computational difficulty.
The least informative prior variance, denoted as σ2LI , is the prior variance that
results in β being equally likely of belonging to any of the J intervals, i.e., all doses
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being a priori equally likely of being the MTD. These J probabilities can be regarded
as being from a discrete uniform distribution, although it is usually not possible to
make them exactly equal. Instead, Lee and Cheung (2011) defined σ2LI as the prior
variance such that the variance of the J probabilities matches (J2−1)/12, the variance
of a discrete uniform distribution. Although σ2LI is uninformative in terms of the prior
model-based MTD distribution, the value of σ2LI is usually not large with respect to
what is usually considered to be an uninformative variance.
For example, in the setting where there are five dose levels, the skeleton is {0.05,
0.10, 0.20, 0.35, 0.50}, the target η is 0.20 and a logistic model with intercept 3
is used, the resulting five intervals of β in which doses 1 to 5 are the MTD are
I1 = (−∞,−0.23), I2 = (−0.23,−0.08), I3 = (−0.08, 0.10), I4 = (0.10, 0.29) and I5 =
(0.29,∞), respectively. The least informative prior variance σ2LI is 0.322, which would
usually be regarded as an informative prior variance in general Bayesian applications.
2.3 Methods for Adaptive Variance Calibration
2.3.1 Defining a Large Prior Variance σ2HI
When the MTD defined by the skeleton is not the first or last dose, a prior variance
larger than σ2LI would result in a U-shaped distribution of the a prior model-based
MTD (Lee and Cheung 2011). As a result, dose 1 and J would be more likely to be
selected as the MTD. Hence, σ2LI could perform poorly when the MTD is the lowest
or highest dose and the MTD defined by the skeleton lies elsewhere, at least when
no stopping rule is used. Therefore, we further define a larger prior variance, σ2HI ,
as the prior variance that satisfies Pr(β ∈ I1 ∪ IJ) = 0.8, producing a U-shaped
distribution for the model-based MTD. Presumably, σ2HI could perform well when
σ2LI performs poorly. A value other than 0.80 can certainly be used to determine
the value of σ2LI . However, values larger than 0.80 will place more mass in the tails
of the MTD distribution and may be too aggressive in situations when the MTD is
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not the highest dose. Conversely, values smaller than 0.80 will place less mass in the
tails of the MTD distribution and will lessen the ability to find the MTD when it
is the highest dose. We found that 0.80 was a good compromise between these two
situations.
2.3.2 CRM-VC1: Increasing the Prior Variance With the Sample Size
We denote CRM-VC1 as our first approach to adaptively calibrate the prior vari-
ance in the CRM. Since the sample size is small early in a trial, it may be appropriate
to use σ2LI at the beginning of a trial so that each dose is a priori equally likely to be
selected as the MTD. However, it would not be desirable for the prior to dominate the
data (Iasonos and OQuigley 2011), especially when the MTD is the lowest or highest
dose. Hence, a sufficiently large prior may be preferred later in a trial. One natural
approach is to start the prior variance at σ2LI and increase it to σ
2
HI at a rate based
upon n, the number of currently enrolled patients. We have selected five different
functions explaining how the prior variance increases with n so that different rates of
change could be captured:




HI − σ2LI)(n− 1)4/(N − 1)4




HI − σ2LI)(n− 1)2/(N − 1)2




HI − σ2LI)(n− 1)/(N − 1)




HI − σ2LI) log(2n− 1)/ log(2N − 1)




HI − σ2LI)(n− 1)/(N2 − 1)− (σ2HI − σ2LI)(n− 1)2/(N2 − 1).
Figure 2.1 displays the five different patterns when N = 30, σLI = 0.33 and σHI =
1.08, a setting we will further explore in our simulations. These five functions repre-
sent typical variance-sample size relationships: (a) the prior variance increases slowly




























Figure 2.1: CRM-VC1: the prior variance increases with the sample size in five different patterns.
constant rate, and (c) the prior variance increases quickly at first and slowly reaches
σ2HI .
2.3.3 CRM-VC2: A Hypothesis Testing Approach
If we start with a certain prior variance in the CRM, it would be ideal if the accu-
mulating data could help determine whether the current prior variance should change.
If the skeleton specifies the correct MTD, the prior variance should be small and the
prior information is incorporated to enhance estimation of the MTD. Otherwise, it
is preferable to change the prior variance if the data indicate that the skeleton has
misidentified the MTD. This is the motivation for CRM-VC2.
A trial based on CRM-VC2 starts with the prior variance σ2LI . When the data
favors the hypothesis that the MTD is the highest dose but the MTD defined by the
skeleton lies elsewhere, CRM-VC2 increases the prior variance to σ2HI , since a large
prior variance would increase the probability of selecting the tail dose levels due to
the U-shaped distribution. We do not increase the prior variance if the MTD is dose
1, since the use of a stopping rule makes it unnecessary. However, when the MTD
defined by the skeleton coincides with the highest dose, the prior variance determined
by CRM-VC2 would remain at σ2LI since increasing the prior variance is no longer
helpful when the prior information is correct.
The decision to switch from σ2LI to σ
2
HI involves a hypothesis testing approach,
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similar to what Yuan and Yin (2011) proposed for their hybrid design. We propose
three hypotheses: H1 : β ∈ I1, H2 : β ∈ I2 ∪ I3 . . . ∪ IJ−1 and H3 : β ∈ IJ . We also
propose two reasonable bounds bl and bu for β to avoid technical difficulties, that is,
β ∈ [bl, bu] rather than (−∞,∞). Specifically, bl satisfies ψ(x1, bl) = η + 0.05 and
bu satisfies ψ(xJ , bu) = η − 0.05. Although it is guaranteed that bl is smaller than
bu for our model parameterization, such a result may not hold true for all models,
in which case one would switch bl with bu. Via simulation, we also examined using
bounds defined by η ± 0.025 and η ± 0.10 and found little change in the operating
characteristics when using η ± 0.05 (results not shown). Actually, when the true β
falls outside [bl, bu], the true DLT rates for all the J doses would be far away from
the target η, implying that the doses examined would be either too toxic or overly
safe. A trial would hence either be terminated by a stopping rule or quickly find the
highest dose as the MTD.
To be objective, we assign a uniform prior distribution under each hypothesis:
β|H1 ∼ Unif[bl, b1), β|H2 ∼ Unif[b1, bJ) and β|H3 ∼ Unif[bJ , bu]. The marginal










Similarly, we can compute p(Yn|H2) and p(Yn|H3). The posterior probability of Hk,
k = 1, 2, 3, is given by
p(Hk|Yn) =
p(Hk)p(Yn|Hk)
p(H1)p(Yn|H1) + p(H2)p(Yn|H2) + p(H3)p(Yn|H3)
.
If we let BFhk = p(Yn|Hh)/P (Yn|Hk), h = 1, 2, 3, denote the Bayes factor for com-
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paring Hh and Hk, then
p(Hk|Yn) =
p(Hk)
p(H1)BF1k + P (H2)BF2k + P (H3)BF3k
.
We specify p(H1) = P (H2) = P (H3) = 1/3 and use Jeffreys’ rule that log10(BFkk′) >
1/2 indicates substantial evidence in favor of Hk against Hk′ (Jeffreys, 1961). This
rule translates to the criterion that if p(H3|Yn) > 0.61, then there is substantial
evidence that β ∈ IJ . Once such evidence exists, the prior variance would increase to
σ2HI ; otherwise, the prior variance stays at σ
2
LI .
2.3.4 CRM-VC3: Adaptively Changing Skeletons
Instead of changing the prior variance during a trial to make the MTD more likely
to be selected, CRM-VC3, our third approach to calibrate the prior variance, is to
modify the skeleton adaptively but keep the prior variance constant. Consequently,
the intervals I1, . . . , IJ would also change, because the intervals I1, . . . , IJ only depend
on the skeleton and the model used. If we can properly adjust these intervals, more
mass of the prior distribution could be placed over the interval that results in selecting
the correct MTD.
For CRM-VC3, a trial starts with the prior variance σ2LI and once the new esti-
mates for πj, are obtained, the dose values would be rescaled again and used as the
new dose values. Let β̃n denote the posterior mean of β after n subjects have finished
follow-up for DLT and let x∗j,0 = x
∗
j . The updated skeleton p
n
j is set equal to the











Skeletons and rescaled dose values are updated according to (2.3) and (2.4) during
a trial. All other facets of the design, including the model and prior distribution,
remain the same. The resulting intervals I1 . . . IJ would change adaptively with the
updating of β̃. Consider the setting where there are five dose levels, the skeleton
is {0.05, 0.10, 0.20, 0.35, 0.50}, the target η is 0.20 and the model used is a logistic
model with intercept 3. Figure 2.2 shows that we could assign more mass to tail
areas adaptively if β̃ falls in I1 or IJ . After the first subject is observed, if β̃ = 0,
the new skeleton will be the same with the original skeleton, indicating the prior
information is close to the truth. As a result, the J intervals and the resulting areas
under the prior density curve for the J intervals do not change since we are using σ2LI
as the prior variance; see Figure 2.2 (a). This is reasonable because the data suggests
that the MTD does not lie in the tail. If β̃ = log(3/2), suggesting the MTD is dose 5.
The prior density will place more mass in I5 after rescaling the dose values with the
area under I5 = 0.64; see Figure 2.2 (b). If β̃ = log(2/3), suggesting the MTD is dose
1, the prior density places more mass on I1 after rescaling the dose values with the
area under I1 = 0.70; see Figure 2.2 (c). As more subjects enter the study, β̃ becomes
more accurate and the resulting updated skeleton is driven by the data, avoiding the
effect that a misspecified skeleton would have in the conventional CRM. One may
be concerned that the updated skeleton values may be unstable early in the study
when little data exists and restrict the use of CRM-VC3 after a minimum sample size
has been accrued. However, restricting any skipping of doses during escalation will
alleviate any possible instability. Furthermore, we examined the mean dose assigned
to the first ten subjects in the settings presented in Section 2.4 (results not shown)
and found that using CRM-VC3 was no more or less stable than the other methods.
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(a) σ = 0.32 , β~ = 0

























(b) σ = 0.32 , β~ = log(3 2)

























(c) σ = 0.32 , β~ = log(2 3)
Figure 2.2: Areas under the Normal prior density curve of β with mean zero and variance σ2LI = 0.32
2
for intervals I1 to I5: S1 to S5. They are also the prior probabilities for selecting each of the five
doses as the MTD. Rescaling the doses sequentially could change the area under the curve for each
interval. The four vertical lines stand for the boundaries for the five intervals.
2.4 Simulation Results
2.4.1 Rules Used in Simulation
We use a cohort size of one subject in our study. Like most dose-finding studies,
we restrict dose escalation to be no more than one dose above the assignment of
the most recent subject. However, we do not impose any restriction on dose de-
escalation. Also, the first subject is always assigned to the lowest dose. However, in
the simulations of the hypothetical trial of Lee and Cheung (2011), the third dose is
assigned to the first subject in order to make our results comparable to theirs.
The prior variance (CRM-VC1 and CRM-VC2) or skeleton (CRM-VC3) will be
updated after a new subject finishes follow-up for DLT. For patient safety, we will
stop the trial if at least two out of the first three patients experience DLT, or, if
Pr(π1 > η|Yn) > 0.9 after four or more patients have been enrolled. In order
to reduce the sensitivity to the prior variance and instability due to small sample
size, our stopping rule mimics the 3+3 method for the first three subjects and then
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switches to use of the posterior probability that the DLT rate for the lowest dose is
above the target. The threshold of 0.9 was found to work well in simulations but could
be adjusted depending upon how great the need for early stopping is. We performed
2, 000 simulations in each scenario; all simulations were done in the statistical package
R (R Development Core Team 2008), the code for which is available upon request.
2.4.2 A Hypothetical Trial
In our hypothetical clinical trial of N = 30 subjects with five dose levels and
the target DLT rate η = 0.20, we used the logistic model with intercept 3. The
prior distribution for β was normal with mean 0 and variance σ2n. We considered
two commonly used skeletons that specify the a priori MTDs to be the middle dose
and the highest dose. Specifically, Skeleton 1 is {0.05, 0.10, 0.20, 0.35, 0.5} (σLI =
0.32; σHI = 1.04) and Skeleton 2 is {0.01, 0.04, 0.07, 0.11, 0.20} (σLI = 0.35; σHI =
0.68). We examined the performances of CRM-VC1, CRM-VC2 and CRM-VC3 in five
different scenarios under both Skeleton 1 and 2 based on the percentage of simulations
selected as the MTD and the average number of patients assigned to each dose. The
true MTDs are doses 1 to 5 for the scenarios 1 to 5, respectively. We also performed
the traditional CRM using the fixed prior variances σ2LI and σ
2
HI in the same five
scenarios for comparison.
The performances under each scenario are summarized in the final eleven columns
of Table 2.2 and Table 2.3 for Skeleton 1 and 2, respectively. The first five of the
eleven columns display the percentage of simulations in which each dose was identified
as the MTD at the end of the study, and the last five columns display the average
number of patients assigned to each dose. For each scenario, we list the true toxicity
probabilities in the first row, the results for the CRM using the fixed prior variance
σ2LI and σ
2
HI in rows 2-3, the results obtained by CRM-VC1 using functions (1) and
(2) in Section 3.2 in rows 4-5, the results obtained by CRM-VC2 in row 6 and the
results obtained by CRM-VC3 in row 7. We do not present the results for CRM-VC1
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using functions (3) to (5) as they did no better or worse than functions (1) and (2).
We note that in general, we have found that all five functions perform similarly in
terms of finding the correct MTD, indicating that there is no real need to choose
among them in application.
In Table 2.2, we note that the traditional CRM is sensitive to the value of the
prior variance. Using the prior variance σ2LI , a similar approach with Method A1
in Lee and Cheng (2011), performs better than using σ2HI in Scenarios 2, 3 and 4,
where the true MTD is close to the MTD defined by the skeleton. But using σ2LI
performs poorly relative to σ2HI in Scenario 5 where the true MTD is the highest dose
but the MTD defined by the skeleton is dose 3. Overall, the CRM using σ2HI is more
robust than using σ2LI in finding the MTD except when the true MTD is at or close to
the skeleton MTD. We also see that using a large prior variance could produce more
unnecessary early stopping. For example, in Scenario 1, using σ2HI results in 44%
early stopping compared with 36% when using σ2LI . This is why the prior variance
does not increase to σ2HI in CRM-VC2 when there is evidence that the true MTD is
dose 1.
CRM-VC1 gives comparable results with the traditional CRM using σ2LI when
the true MTD is similar to that specified by the skeleton, but performs much better
when the true MTD is the highest dose. Compared with the traditional CRM using
the prior variance σ2HI , CRM-VC1 performs slightly better in Scenario 1, 2 and 3 and
has comparable performance in scenarios 4 and 5. CRM-VC2 performs consistently
well overall, even though it performs slightly worse than other competing methods
in Scenario 4. CRM-VC2 performs as well as the CRM using the prior variance σ2LI
in Scenario 1, 2 and 3, but CRM-VC2 performs much better in Scenario 5 where the
true MTD is dose 5. Compared with the traditional CRM using σ2HI , CRM-VC2 also
demonstrates a better ability in identifying the MTD: 61% versus 56% in Scenario 2
and 65% versus 59% in Scenario 3. CRM-VC3 performs similarly with the traditional
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CRM using the prior variance σ2HI .
We also see that the design giving a higher probability of selecting the MTD also
assigns more patients to the correct dose. Hence, similar results are obtained if we
compare mean dose assignments among the methods examined. Overall, CRM-VC2
performs best among all the methods examined across the five scenarios. It is also
common in practice that the MTD determined by the skeleton is the highest dose.
Skeleton 2 is one such skeleton. When using Skeleton 2 while keeping other facets
of the design unchanged, we notice that the results presented in Table 2.3 are quite
similar among the five scenarios for most of the methods examined. However, CRM-
VC2 and the traditional CRM using prior variance σ2LI slightly outperform other
methods across the five scenarios.
2.4.3 A Hypothetical Trial in Lee and Cheung (2011)
In this setting, there are N = 25 subjects, six dose levels and the target DLT
rate is η = 0.20. The first patient is assigned to dose 3 and the model used is the
power model. In order to make our results comparable to those of Lee and Cheung, we
used the skeleton {0.05, 0.11, 0.20, 0.31, 0.42, 0.53} (σLI = 0.68; σHI = 2.45) used with
Method A1 of Lee and Cheung, which we denote as LC-A1. Table 2.4 contains results
obtained from the traditional CRM, LC-A1, CRM-VC1, CRM-VC2 and CRM-VC3
in the similar scenarios examined by Lee and Cheung. Note that LC-A1 is equivalent
to the traditional CRM using the prior variance σLI in this example because the
skeleton is the same for both methods.
In Scenario 1, all the methods work similarly. The traditional CRM using prior
variance σ2HI results in more trials being terminated than using σ
2
LI . In Scenarios 2 and
3, LC-A1, CRM-VC2 and the traditional CRM using σ2LI perform slightly better than
other approaches; all three approaches correctly identify the MTD in approximately
55% of simulations in contrast to 49-53% for the other approaches. However, LC-A1
and the traditional CRM using σ2LI perform poorly relative to CRM-VC2 in Scenario
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Table 2.2: Simulation study comparing the CRM-VC1, CRM-VC2 and CRM-VC3 with the tradi-
tional CRM under Skeleton 1: {0.05, 0.10, 0.20, 0.35, 0.5}. “None” denotes the proportion of trials
that stop early. Numbers 1-5 in the first row stand for dose 1 to 5. Numbers in bold indicate which
dose is the MTD.
Percentage of simulations Mean number of
selected as MTD subjects assigned
Scen None 1 2 3 4 5 1 2 3 4 5
1 Pr(DLT) 0.20 0.30 0.35 0.45 0.50
CRM σ2LI 17 44 29 9 1 0 11 9 5 1 0
σ2HI 32 36 23 8 1 0 11 6 3 1 1
CRM-VC1 1 23 47 21 7 1 0 12 8 4 2 0
2 26 43 24 9 1 0 11 9 5 1 0
CRM-VC2 18 44 28 9 1 0 10 8 6 2 0
CRM-VC3 34 36 20 8 1 0 10 6 4 1 1
2 Pr(DLT) 0.10 0.20 0.35 0.45 0.50
CRM σ2LI 4 15 62 16 1 0 6 14 7 2 0
σ2HI 6 18 56 19 2 0 8 12 6 2 1
CRM-VC1 1 4 22 57 22 2 0 7 13 7 2 0
2 4 20 56 19 1 0 7 13 7 2 0
CRM-VC2 4 15 61 19 1 0 6 14 7 2 0
CRM-VC3 9 18 55 17 2 0 8 12 6 2 1
3 Pr(DLT) 0.05 0.10 0.20 0.35 0.45
CRM σ2LI 0 1 19 66 13 0 2 7 15 5 0
σ2HI 2 1 19 59 18 1 3 7 12 6 2
CRM-VC1 1 0 1 23 61 14 1 2 7 14 6 1
2 2 1 19 60 18 1 2 7 13 6 1
CRM-VC2 0 1 20 65 14 1 2 7 15 5 1
CRM-VC3 2 1 20 61 15 1 3 7 12 6 2
4 Pr(DLT) 0.02 0.05 0.10 0.20 0.35
CRM σ2LI 0 0 1 28 61 10 1 2 10 14 3
σ2HI 0 0 1 23 60 16 2 3 7 12 7
CRM-VC1 1 0 1 1 25 58 16 1 2 9 14 4
2 0 0 1 21 61 16 1 2 8 13 5
CRM-VC2 0 0 1 27 56 16 1 2 9 12 5
CRM-VC3 0 0 1 23 60 15 2 3 7 12 7
5 Pr(DLT) 0.01 0.04 0.07 0.11 0.20
CRM σ2LI 0 0 0 7 37 56 1 2 5 12 11
σ2HI 0 0 0 4 27 69 1 2 3 7 16
CRM-VC1 1 0 0 0 6 28 66 1 2 4 11 12
2 0 0 0 4 27 68 1 2 4 9 14
CRM-VC2 0 0 0 6 26 68 1 2 4 8 14
CRM-VC3 0 0 0 5 25 70 1 2 3 7 17
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Table 2.3: Simulation study comparing the CRM-VC1, CRM-VC2 and CRM-VC3 with the tradi-
tional CRM under Skeleton 2: {0.01, 0.04, 0.07, 0.11, 0.20}. “None” denotes the proportion of trials
that stop early. Numbers 1-5 in the first row stand for dose 1 to 5. Numbers in bold indicate which
dose is the MTD.
Percentage of simulations Mean number of
selected as MTD subjects assigned
Scen None 1 2 3 4 5 1 2 3 4 5
1 Pr(DLT) 0.20 0.30 0.35 0.45 0.50
CRM σ2LI 18 41 30 8 1 0 9 9 4 2 1
σ2HI 26 44 24 5 1 0 13 7 3 2 1
CRM-VC1 1 21 46 26 6 1 0 10 8 4 2 1
2 22 45 26 8 2 0 10 9 4 2 1
CRM-VC2 18 41 30 8 1 0 9 9 4 2 1
CRM-VC3 31 43 20 5 1 0 12 6 3 1 1
2 Pr(DLT) 0.10 0.20 0.35 0.45 0.50
CRM σ2LI 6 16 60 17 2 0 5 13 7 3 1
σ2HI 5 20 57 14 2 0 8 12 5 2 1
CRM-VC1 1 6 20 57 16 2 0 5 13 6 3 1
2 6 16 57 17 3 1 6 13 6 3 1
CRM-VC2 6 16 60 17 2 0 5 13 7 3 1
CRM-VC3 9 21 55 14 2 0 9 11 5 2 1
3 Pr(DLT) 0.05 0.10 0.20 0.35 0.45
CRM σ2LI 1 1 22 54 21 2 2 7 11 7 3
σ2HI 1 2 25 49 22 2 3 8 10 6 3
CRM-VC1 1 1 1 29 49 20 2 2 8 11 7 3
2 2 1 26 49 20 2 2 8 11 7 3
CRM-VC2 1 1 22 54 21 2 2 7 11 7 3
CRM-VC3 2 2 29 50 17 1 3 8 10 6 3
4 Pr(DLT) 0.02 0.05 0.10 0.20 0.35
CRM σ2LI 0 0 3 22 58 18 1 2 6 12 8
σ2HI 0 0 2 21 55 22 2 3 6 11 9
CRM-VC1 1 0 0 3 22 58 18 1 2 6 12 8
2 0 0 2 23 54 21 1 2 6 12 9
CRM-VC2 1 0 3 22 58 18 1 2 6 12 8
CRM-VC3 0 0 3 24 55 18 2 3 7 11 8
5 Pr(DLT) 0.01 0.04 0.07 0.11 0.20
CRM σ2LI 0 0 0 2 23 75 1 1 2 7 19
σ2HI 0 0 0 2 23 75 1 2 2 6 18
CRM-VC1 1 0 0 0 3 23 73 1 1 2 7 18
2 0 0 0 2 22 75 1 1 2 6 19
CRM-VC2 0 0 0 2 23 75 1 1 2 7 19
CRM-VC3 0 0 1 4 23 73 1 2 3 6 18
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5 where the MTD is the highest dose.
As seen earlier, the traditional CRM using σ2HI does not perform as well as σ
2
LI in
Scenarios 2 and 3 where the true MTD is close to the MTD defined by the skeleton,
even though the difference is not large. CRM-VC1 and CRM-VC2 performs as well
as or better than LC-A1 in Scenarios 2,3 and 4 but performs better than LC-A1 in
Scenario 5. CRM-VC3 performs similarly with the traditional CRM using σ2HI . We
also see that the design giving a higher probability of selecting the MTD also assigns
more patients to the correct dose. Hence, similar results are obtained if we compare
mean dose assignments among the methods examined. Overall, in this setting, CRM-
VC2 and CRM-VC3 seem to perform best among all the methods examined in terms
of the ability of identifying the MTD across the five scenarios.
2.5 Discussion
In the present project, we relax the assumption of a fixed prior variance in the
traditional CRM and propose three systematic approaches to adaptively calibrate the
prior variance continually throughout the trial. Our approaches have the ability to
perform better than the traditional CRM using a constant prior variance as well as
methods that calibrate the prior variance only at the beginning of the trial.
Although Lee and Cheung (2011) suggested using σ2LI after first calibrating the
skeleton at the beginning of the trial, this approach does not perform well when the
true MTD is far away from the MTD defined by the skeleton. Although Lee and
Cheung proposed an alternate, computationally intensive design, which we refer to
as LC-A2, we found that LC-A2 generally offers no improvement to the results of
LC-A1. Our approaches, however, are able to improve upon the results of LC-A1 in
scenarios where the MTD is the highest dose without sacrificing the performance much
in other scenarios, and are less computationally expensive than LC-A2. However, as
seen in our simulation results, our methods might be more aggressive than the CRM
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Table 2.4: Simulation study comparing the CRM-VC1, CRM-VC2 and CRM-VC3 with the method
LC-A1 and the traditional CRM in scenarios examined by Lee and Cheung. The column “None”
denotes the proportion of trials that stop early. The numbers 1-6 in the first row denote dose 1 to
6. Numbers in bold indicate which dose is the MTD.
Percentage of simulations Mean number of
selected as MTD subjects assigned
Scen None 1 2 3 4 5 6 1 2 3 4 5 6
1 Pr(DLT) 0.20 0.35 0.50 0.61 0.76 0.87
CRM σ2LI 37 44 18 1 0 0 0 8 6 3 1 0 0
σ2HI 43 43 14 1 0 0 0 11 4 4 2 1 0
LC-A1 37 44 18 1 0 0 0 8 6 3 1 0 0
CRM-VC1 1 44 43 13 1 0 0 0 8 5 3 1 0 0
2 45 42 14 0 0 0 0 8 5 3 1 0 0
CRM-VC2 39 44 16 1 0 0 0 8 6 3 0 0 0
CRM-VC3 41 44 14 1 0 0 0 10 4 3 1 0 0
2 Pr(DLT) 0.05 0.10 0.20 0.30 0.50 0.70
CRM σ2LI 5 1 21 51 22 1 0 1 5 11 6 1 0
σ2HI 4 3 22 49 22 1 0 3 5 9 5 2 1
LC-A1 5 1 21 51 22 1 0 1 5 11 6 1 0
CRM-VC1 1 4 2 22 47 22 2 0 1 5 11 6 1 0
2 5 1 22 48 22 2 0 1 6 10 6 1 0
CRM-VC2 4 1 20 52 21 2 0 1 5 11 5 1 0
CRM-VC3 4 2 22 48 22 1 0 2 5 10 5 2 1
3 Pr(DLT) 0.06 0.08 0.12 0.18 0.40 0.71
CRM σ2LI 3 0 4 27 55 11 0 0 2 8 10 3 0
σ2HI 2 1 7 27 49 14 0 2 2 7 9 4 1
LC-A1 3 0 4 27 55 11 0 0 2 8 10 3 0
CRM-VC1 1 3 1 5 23 53 16 0 0 2 8 10 3 0
2 3 0 5 25 52 15 0 1 2 8 10 4 0
CRM-VC2 3 0 5 27 54 12 0 0 2 9 10 3 1
CRM-VC3 2 1 6 26 52 14 0 1 2 8 9 4 1
4 Pr(DLT) 0.05 0.06 0.08 0.11 0.19 0.34
CRM σ2LI 1 0 1 8 33 46 11 0 1 5 8 8 3
σ2HI 1 0 2 6 23 47 20 1 1 3 6 8 6
LC-A1 1 0 1 8 33 46 11 0 1 5 8 8 3
CRM-VC1 1 2 0 1 7 23 45 22 0 1 5 7 8 4
2 1 0 1 7 25 45 20 0 1 5 7 8 5
CRM-VC2 2 0 1 8 26 43 21 0 1 5 7 6 5
CRM-VC3 1 0 2 7 23 46 21 1 1 4 5 7 6
5 Pr(DLT) 0 0 0.03 0.05 0.11 0.22
CRM σ2LI 0 0 0 0 7 43 50 0 0 3 5 9 8
σ2HI 0 0 0 0 4 30 65 0 0 2 3 7 13
LC-A1 0 0 0 0 7 43 50 0 0 3 5 9 8
CRM-VC1 1 0 0 0 0 4 29 66 0 0 3 4 8 10
2 0 0 0 0 4 31 64 0 0 3 4 7 11
CRM-VC2 0 0 0 0 6 29 65 0 0 3 5 6 12
CRM-VC3 0 0 0 0 4 28 68 0 0 3 3 6 13
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using σ2LI in certain scenarios. Nonetheless, the CRM-VC2 and CRM-VC3 can be
modified to be less conservative by simply changing some of the thresholds used in
those methods. For example, we could increase the threshold of 0.61 for the posterior
probability of H3 in CRM-VC2 to a larger value, in which case the performance would
be similar to that of Lee and Cheung. However, we note that there is no one value
for the threshold that will work best in all scenarios and we feel our threshold is a
good choice in most scenarios.
One reviewer questioned whether or not our designs are coherent in the sense that
dose escalation is possible when the most recent patient experiences a DLT (Cheung
2005). In the scenarios of Section 2.4.3, escalation after a DLT never occurred, and
in the scenarios of Section 2.4.2, the dose escalation never occurred after an observed
DLT in more than 3% of simulations. Thus, although there is no guarantee of coher-
ence of our designs in all settings, any deviation from coherence is quite small and
patient safety is not compromised.
Our approaches could be extended to accommodate a wider range of applications.
CRM-VC1 could be easily applied to more complex studies, including finding the
most successful dose or the most tolerated schedule , once we determine σ2LI and σ
2
HI .
CRM-VC2 and CRM-VC3 rely on the skeleton and hence could be naturally extended
to a study where a skeleton is specified and the dose values are rescaled, for example
modeling the toxicity in the study of finding the MSD. For a model with more than
two parameters, CRM-VC2 and CRM-VC3 are still applicable even though it may be
hard to find the indifference regions in high-dimensional parameter space.
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CHAPTER III
A Phase I Bayesian Adaptive Design to
Simultaneously Optimize Dose and Schedule
Assignments Both Between and Within Patients
3.1 Introduction
Traditional Phase I trials assign a dose of a therapeutic agent to each subject
and the subject receives that dose in a single administration. However, if the agent
is safe at that dose, reason suggests that the patient should be given additional
administrations of the agent at the same, or perhaps different, doses in hopes of
maximizing any efficacy the agent may have with regard to treating or preventing
disease.
Such was the motivation of the Phase I trial described by de Lima, et al. (2010).
Chemotherapy is often the first treatment given to patients with acute myelogenous
leukemia (AML) or advanced myelodysplastic syndrome (MDS). If chemotherapy fails
to force remission of a patient’s cancer, the next course of treatment is an allogeneic
hematopoietic stem cell transplant (HSCT). Although short-term complete remission
(CR) of cancer frequently occurs after HSCT, long-term cancer recurrence is still
quite prevalent in HSCT recipients. Therefore, researchers hope to find interventions
that can be given not only in proximity to HSCT, in order to promote a short-
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term CR, but also repeatedly after HSCT in order to maintain a CR for a longer
period of time. One such intervention is azacitidine; however, the safety profile for
multiple administrations of different doses of azacitidine in AML and MDS patients
was unknown, thereby necessitating the design of the Phase I trial to address this
question.
At the time that the azacitidine trial was being considered, there were no published
designs for simultaneous dose- and schedule-finding in Phase I trials. Although Braun,
Zheng, and Thall (2004) proposed a design in which the time to toxicity was modeled
using a triangular hazard model for each administration, their model assumed a single
dose was under study. Liu and Braun (2009) later developed a more flexible model for
the cumulative hazard of a dose-limiting toxicity (DLT) by introducing a non-mixture
cure rate model and a smooth hazard function. However, their methods also assumed
a single dose was being considered.
To meet the needs of the azacitadine trial, Braun et al. (2007) developed the first
design for dose- and schedule-finding by generalizing the work of Braun et al. (2004)
to incorporate different triangular hazard functions for each dose. However, as noted
by Liu and Braun (2009), the method of Braun et al. (2004) can be inflexible mainly
due to its computational difficulty, the finite support of the triangular hazard function
and the difficulties with including patient-level or administration-level covariates.
The azacitidine Phase I trial was designed to identify which combination of three
doses and four administration schedules was the maximum tolerated combination
(MTC) of dose and schedule, defined as the combination estimated to have the prob-
ability of a DLT within 116 days of starting treatment closest to 0.30. In the design,
each patient was adaptively assigned to whichever dose and schedule combination
was believed to be the MTC, based upon the data collected on previously enrolled
patients. One important characteristic of this trial was that once enrolled, a patient’s
dose and/or schedule was to remain unchanged, except for reductions in dose and/or
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number of administrations due to complications unrelated to azacitidine such as infec-
tion. In the actual trial, three patients received reduction in their assigned dose, and
about half of the patients had reductions to their planned number of administrations.
However, one could also envision patients who were assigned to combinations that
during the trial are determined to have DLT rates well below that of the MTC. Pa-
tients assigned to such combinations who have not completed all their administrations
might benefit from increases to the dose and/or number of administrations they re-
ceive. Such changes are not necessarily expected to increase correct identification of
the MTC at the end of the study, but should increase the number of subjects during
the trial who are assigned to combinations near the MTC. Although the model of
Braun et al. (2007) could allow the possibility that the patient’s planned dose for
each administration to be changed, the benefit of patient reassignments, as well as
how and when appropriate reassignments of doses and/or schedules are determined,
are areas that have not been studied.
These issues are the motivation of our current work. First, we generalize the
methods of Liu and Braun (2009) to simultaneously optimize the dose and schedule
assigned to each patient. Specifically, we extend their Bayesian non-mixture cure
model by incorporating the per-administration dose as a covariate for modeling the
cure fraction to allow for multiple dose levels. In addition, we derive a non-mixture
cure rate model through a competing risks approach to accommodate multiple ad-
ministrations one patient may receive. The second contribution of our work is to
adaptively optimize the dose and schedule assignments both between patients and
within patients. While new patients are given the most recent maximum-tolerated
dose-schedule combination (MTC) estimate, our approach also re-evaluates the esti-
mated DLT rate for the current assignment of each enrolled patient and automatically
determines whether dose-schedule reassignment is needed. Patient accrual, data mon-
itoring, and outcome-adaptive decision-making are done continuously throughout the
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trial under a Bayesian formulation. We describe the probability model and the dose-
schedule-finding algorithm in Section 3.2, and we illustrate the proposed design in
the context of a real trial and present a simulation study in Section 3.3. We conclude
with a brief discussion in Section 3.4.
3.2 Methods
3.2.1 Preliminary Notation
Typical dose-schedule finding trials aim to find the MTC within a J ×K matrix
consisting of J per-administration doses and K nested schedules. We denote the
administration times for schedule k, k = 1, . . . , K, as s(k) = {s1, s2, . . . , smk} such
that s(1) ⊂ s(2) ⊂ · · · ⊂ s(K) and m1 < m2 < · · · < mK , where mk is the number
of administrations for schedule k. We focus on nested schedules because they have
natural ordering and hence are of interest to the clinicians.
In our motivating example, there are J = 3 doses and K = 4 nested schedules.
A course of administrations corresponds to daily administrations for the first 5 days
followed by 24 days of rest, which we denotes as (5+, 24-). The first schedule is com-
prised of one single course, so the administration times s(1) = {0, 1, 2, 3, 4}. Schedule
2 consists of two courses with the additional course starting 28 days after the be-
ginning of s(1), we have s(2) = {0, 1, 2, 3, 4, 28, 29, 30, 31, 32} =
{
s(1), s(1) + 28
}
, and
so on. Ideally, we plan to give dose j = 1, 2, . . . J , at each administration in s(k),
and we let dj denote the per-administration dose. The number of subjects enrolled
by the end of the trial is N and each subject will be followed up to the maximum
follow-up time ω = 116 days, which is determined by the clinical investigators and
is a clinically meaningful duration of time that is sufficiently late enough to observe
DLTs attributed to the longest schedule. A target DLT rate η = 0.30 is also elicited
from clinicians and is defined as the targeted probability of cumulative toxicity by ω.
Note that dj and s
(k) represent the combinations of doses and schedule that are
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possible assignments to each patient as they enter the study. In contrast, during
a trial, the actual number of administrations and the dose at each administration
for each patient may differ from each of those possible combinations. To make this
concept distinct, we let si = {si,1, . . . , si,mi} , i = 1, . . . , N, denote the successive
times at which patient i receives the agent and let di = {di,1, . . . , di,mi} where di,l ∈
{1, . . . , J} and l = 1, . . . ,mi denote the per-administration doses for patient i at the
administration times si.
3.2.2 Model for Time-to-DLT After a Single Administration
As noted by Liu and Braun (2009), a significant proportion of patients are “cured,”
i.e. never experience DLTs after a single administration. Thus, they chose to model
the time-to-DLT for a single administration using the non-mixture cure model pro-
posed by Chen, Ibrahim, and Sinha (1999). Specifically, we take a standard cumu-
lative distribution function F (ν|φ) with parameters φ, with a corresponding density
function f(ν|φ), and scale F (ν|φ) by a parameter θ > 0 to create the respective
survival and hazard functions S(ν|θ,φ) = exp[−θF (ν|φ)] and g(ν|φ, θ) = θf(ν|φ).
We adopt S(ν|θ,φ) as the probability of no DLT by follow-up time ν after a single
administration and interpret θ as a cure rate parameter because the cure fraction
S(∞) = exp(−θ) is determined solely by θ. The Time-to-Event CRM (TITE-CRM)
of Cheung and Chappell (2000) for traditional dose-finding can be viewed as a mix-
ture cure model for the time-to-DLT, as outlined in Braun (2005). However, we have
chosen to use a non-mixture cure rate model instead of a mixture cure model be-
cause the latter does not have a proportional hazards structure and is less feasible
for Bayesian computations (Chen, Ibrahim, and Sinha 1999; Tsodikov, Ibrahim, and
Yakovlev 2003).
However, the non-mixture cure model used by Liu and Braun (2009) must be ex-
tended to allow the cure fraction to vary by dose. To that end, we model the cure rate
fraction for administration l of patient i as log(θi,l) = β0 + exp(β1)di,l,−∞ < β0, β1 <
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∞, so that θi,l > 0. Note that we exponentiate β1 to ensure that the probability of
DLT after a single administration increases with dose. As a result, the respective haz-
ard and survival functions for a single administration l are g(νi,l|β,φ) = θi,lf(νi,l|φ)
and S(νi,l|β,φ) = exp[−θi,lF (νi,l|φ)], in which β = (β0, β1). Thus, our proposed
hazard is an increasing function of dose through the cure fraction, even though the
parameters in f(·) do not involve dose. We feel that the log-linear model should be
adequate in many settings for identifying the MTC since the sample size is usually
small in Phase I trials and the overall model fit is not our primary interest (O’Quigley
et al. 1990). However, if one were truly concerned about the log-linear assumption,
one could always add more parameters in the model if needed. Although compu-
tationally challenging relative to the small sample size, one could propose several
competing models and use Bayesian Model Averaging or select the best-fitting model
at each interim analysis time as outlined by Raftery, Madigan, and Hoeting (1997)
and Ying and Yuan (2009).
With regard to f(·), we adopt the model of Liu and Braun (2009), a two-parameter




with φ = (α, γ). Such
a choice has biologic appeal because the resulting hazard function increases with time
to a certain time point and then attenuates afterward, as was suggested by clinical
investigators in the azacitidine trial. Mathematically, we expect the mode of the
hazard function to exist at exp(γ/α)(1 − 1/α)1/α, and we assume α > 1 so that the
mode exists.
We did consider modeling φ as a function of dose, but did not because doing so
would eliminate the proportional hazards structure of our model and there will be
no guarantee that the hazard will increase with dose if φ is also a function of dose.
Further support for our approach is given by Chen, Ibrahim and Sinha (1999), who
examined the standard cure model without proportional hazards and found both mod-
els (with or without proportional hazards) led to similar point and interval estimates.
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We also ran simulations (results not shown) with φ varying with dose and found
that this added level of complexity to our model offered no benefit to identification
of the MTC. The main reason for this result is Phase I trials seek to estimate well
the DLT rate of the MTC and not necessarily the DLT rates for all dose-schedule
combinations. Thus, overall model fit is not the primary interest and we prefer a
parsimonious model with reasonable flexibility.
Thus the distribution of DLT times is controlled by the four parameters β0, β1, α,
and γ, whose interpretations are as follows. If we denote pi,l as the DLT rate by
the maximum follow-up time ω for a single administration l of patient i, then pi,l =
1− S(ω|β,φ) = 1− exp{− exp[β0 + exp(β1)di,l]F (ω|φ)}. Thus, with infinite follow-
up, we have pi,l = 1− exp{− exp[β0 + exp(β1)di,l]}, which is a complementary log-log
model that could be used in the CRM with binary DLT outcomes. The intercept
β0 quantifies the limiting probability of DLT for a single administration of a dose
di,` = 0, while β1 quantifies how the limiting probability varies with dose. The rate
at which the limiting probability is reached for each dose is controlled by α and γ, in
which α and γ determines the mode of the DLT times and increasing the value of γ
quantifies later DLT times.
3.2.3 Model for Time-to-DLT After Multiple Administrations
We employ a competing risks cure rate model by treating yi,l, the time to the DLT
after administration l of patient i, as a latent variable to incorporate the multiple ad-
ministrations received by each patient. The patient time when patient i experiences a
DLT is then defined as the random variable Yi = min {(s1 + yi,1), . . . , (smi + yi,mi)}.
Therefore, under the assumption of independence of yi,1, . . . , yi,mi , the survival func-
tion for patient i at patient time t, is given by



























where θi,l = exp[β0 + exp(β1)di,l] is the cure parameter and νi,l = t − si,l is the
follow-up time for administration l of patient i. The hazard function is then given by
h(t; |β,φ, si,di) =
∑mi
l=1 θi,lF (νi,l|φ), which indicates the cumulative effect of multiple
administrations.
The assumption that the times-to-DLT after each administration, yi,1, . . . , yi,mi ,
are independent for the mi administrations of the same patient i might not hold,
although the actual amount of correlation is not testable (Tsiatis 1975). A more
general model could be based on an Archimedean copula-type model or a frailty model
with a cure fraction (Hougaard 2000). For example, the above survival function could
be generalized to







which is a Gumbel copula model with a correlation parameter ξ, in which ξ = 0
indicates independent DLT times. Here, we will assume independence for our model
since it is simple and we feel that copula models could possibly impose strong and
untestable assumptions on the correlation structure of DLT times.
Define the observed patient time Ti = min(Yi, Ui) and Ci = I(Yi ≤ Ui), where
Ui denotes the censoring time and I(·) is the indicator function. Hence, we observe
a DLT for patient i if Ci = 1. Since we perform interim analyses whenever a new
patient in enrolled, by the time patient n + 1 is enrolled, we denote the number of
patients currently in the study as n and for each enrolled patient, we observe Ti, Ci, si
and di, where si and di, as we defined previously, are the respective time and dose for
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each administration patient i have received, i = 1, . . . , n. Note Ui = min(Wi,n+1, ω),
where Wi,n+1 the inter-patient time between patient i and n + 1. If n = N , the
maximum number of patients for the study, then define Wi,n+1 as the time between
patient i and the end of the study. It is reasonable to assume random censoring since
Wi,n+1 is usually independent of the DLT time and ω is a fixed value. Based on the
above information, Equations (3.1) and (3.2), the likelihood on the data Di = (Ti =
ti, Ci = ci, si,di) for patient i is given by
L(Ti = ti, Ci = ci|β,φ, si,di) = ψ(ti|β,φ, si,di)1−ciq(ti|β,φ, si,di)ci (3.3)
After determining the prior distribution p(β,φ), then the posterior distribution of




L(Ti = ti, Ci = ci|β,φ, si,di).
We can compute posterior quantities via adaptive Markov Chain Monte Carlo (MCMC)
methods (Rosenthal 2007). Those posterior quantities will be used to identify the
dose-schedule assignment for a new patient and a possibly new dose-schedule assign-
ment for an existing patient as described in Section 3.2.5.
3.2.4 Establishing Prior Distributions
For the two parameters of the cure fraction, β, we assign independent Gaussian
distributions with prior mean and prior variance (µ0, σ
2
0) for β0 and (µ1, σ
2
1) for β1.
In order to determine values for the prior means µ0 and µ1, we ask the investigators
to provide the “skeleton” P , which is a J × K matrix of a priori estimates of the
DLT rates by ω for all dose-schedule combinations, in which element (j, k), denoted
Pjk, corresponds to the combination of dose j and schedule k. We then fit the linear
regression model log(− log[1− Pjk]) = log(mk) + b0 + exp(b1)dj and use the ordinary
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least square estimates b̂0 and b̂1 as the respective values for µ0 and µ1.
For the two parameters of the hazard, φ = (α, γ), we have chosen to make α fixed
to maintain a parsimonious model and limit the number of parameters to estimate.
In addition, preliminary simulations (results not shown) indicated that there was no
meaningful change in operating characteristics when assigning a prior distribution to
α. However, because the mode of the hazard for a single administration monotonically
increases with γ, estimation of γ is important to the performance our algorithm.
Therefore, we assign a Gaussian prior distribution for γ with mean µγ and variance
σ2γ. To determine values for α and µγ, we apply the method outlined in Liu and Braun
(2009) for each dose and calculate the average. If the resulting value for α < 1, we
set α = 1.01, so that the mode exists.




γ as we can
imagine that Phase I trials are usually sensitive to prior variances due to the small
sample size. The prior variances should not be too small, otherwise the prior in-
formation dominates the trial. However, they cannot be too large either since we
hope to incorporate the prior information for possibly more accurate estimation. We
recommend calibrating the prior variances through simulations using a few different
skeletons and prior variances. The prior variance that is the most insensitive to skele-
tons and leads to the best operating characteristics will be used for a real trial. We
present an example of variance calibration related to the simulations of Section 3.3.
3.2.5 Algorithm for Adaptive Assignments for New Patients and Reas-
signments for Enrolled Patients
The algorithm for assigning a dose-schedule combination to a new patient is similar
to that used in the CRM and many other Phase I designs. When a new patient
enters the study, for every combination of a dose j and a schedule k, we compute
p̂jk = 1− ψ̂(ω|φ,β, s(k), dj), the posterior estimate of the DLT rate by the maximum
follow-up time ω. In Phase I studies, ψ̂ is usually approximated by plugging in φ̂ and
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β̂, the respective posterior medians/means of φ and β. Given a desired DLT rate η,
the dose-schedule combination that minimizes a distance measure d(p̂jk, η), which we
denote (j∗, k∗) is assigned to the next patient, subject to one restriction. Both j∗ and
k∗ cannot simultaneously be respectively more than one dose higher than ji−1, the
dose assigned to the most recently enrolled patient, and ki−1, the schedule assigned to
the most recently enrolled patient. Even though we use a “no-skipping” rule for dose-
schedule escalation among successive patients, there is no such rule when it comes
to de-escalation. We place no restriction on escalation of dose and schedule within
a patient, which some may view as overly aggressive. However, in the simulation
results presented in Section 3.3.2, we see no evidence of a higher than desired rate of
DLTs. We also ran simulations in which the between-patient restriction on escalation
to also applied within-patient (results not shown). We saw little change to the results
presented in Table 3.4, except that patient assignments to acceptable combinations
tended to lessen with the restriction than without it.
We adopt the measure d(p̂jk, η) = |p̂jk − η|, although we could adopt a different
metric in order to penalize selection of toxic regimens, like that proposed in the
Escalation with Overdose Control (EWOC) design of Babb, Rogatko, and Zacks
(1998). EWOC selects the dose that minimizes the distance (p̂jk − η)(1 − δ)I(p̂jk >
η) + (η − p̂jk)δI(p̂jk < η), and with δ < 0.5, will penalize the selection of toxic dose-
schedule combinations more than our metric |p̂jk − η|. Furthermore, a stopping rule
for excessive toxicity could be easily incorporated into our design. For example, in
our simulations, we use a stopping rule stating that a trial is halted if at least three
patients have been enrolled and p̂11 > η+ 0.15, in which p̂11 is the DLT rate estimate
for the lowest dose-schedule combination. A similar stopping rule when all DLT rates
are too low could also be used.
We emphasize that reassignment of dose and/or schedule does not apply to pa-
tients who have experienced DLT, nor to those who finished their originally assigned
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treatment, nor those whose treatment was terminated early. For the remaining n∗ ≤ n
patients who are still planning to receive additional administrations, we compute
p̂` = 1 − ψ̂(ω|φ,β, s`,d`), which is the estimated DLT rate of the administrations
received so far by patient ` = 1, 2, . . . n∗. We immediately terminate the treatment
of any patient ` for whom p̂` ≥ η + 0.1, as they have already received a combination
that appears to be overly toxic and further treatment would be unethical. Once the
treatment is terminated, no additional administrations will be given to the patient
but this patient is still under follow-up until a DLT occurs or the maximum follow-up
time ω is reached.
For each of the remaining patients for whom p̂` < η+0.1, we need to consider how
many more administrations might be given and which dose would be given at each
of those administrations. Specifically, if m` is the number of administrations received
so far, we compute δk` = (mk − m`), for each schedule k, including the schedule to
which the patient was originally assigned. Among all schedules with δk` > 0, let s
(k)
`+
denote the remaining administration times for schedule k that could still be assigned
to patient `. We consider the combination of each s
(k)
`+ with each dose j and let d
(jk)
`+
denote the remaining dose assignments, which is a vector of δk` elements each with
the value dj. We then compute P
(jk)




`+ ]), which is
the probability of DLT by ω for patient ` for each of these possible reassignments
appended to what he has already received. We will reassign patient ` according to
whichever P
(jk)
` is closest to the targeted DLT rate, η. We emphasize again that
one of the possible “reassignments” is simply the assignment currently belonging to
patient `.
To clarify our notation, we consider a hypothetical study of J = 3 doses and
K = 5 schedules in which schedule k is comprised of k consecutive (5+, 24−) courses
as described in Section 3.2.1. Imagine that a new patient is to be enrolled in
the study and that we have an enrolled patient ` who was assigned to schedule
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Table 3.1: Nine possible remaining dose and schedule assignments for a hypothetical patient who
has not completed their originally assigned treatment and remains under observation without DLT.
Vectors of remaining administration times are s
(3)









`+ , 112, 113, 114, 115, 116}
.
Dose at Each Times of
Decision Administration Administration
No change 32 s
(3)
`+
























3, has not yet experienced a DLT, and has respective administration times and
doses for each administration s` = {0, 1, 2, 3, 4, 28, 29, 30, 31, 32, 56, 57} and d` =
{8, 8, 8, 8, 8, 16, 16, 16, 16, 16, 32, 32} mg/m2. As each schedule had a total of five
planned administrations, we see that patient ` has completed two courses and has
three administrations remaining in her third course. Assuming that the treatment
received so far does not have an estimated DLT rate 10 points above the target, Ta-
ble 3.1 delineates the nine possible remaining assignments that could now be given to
patient `. Whichever of these nine combinations, when appended to s` and d`, leads
to an estimated DLT rate by ω closest to the target DLT rate is the reassignment
given to patient `.
This example emphasizes the fact that we attempt to keep the dose constant
within a patient as much as possible, i.e. each administration for a patient will be at
the same dose until a reassignment occurs. Thus, the hypothetical patient ` described
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above had already received two previous changes to her assignment, as her dose was
increased from 8 mg/m2, then to 16 mg/m2, and then again to 32 mg/m2. Of course
one could consider a setting in which the best treatment plan would be contrary
to this, i.e. perhaps alternating back-and-forth between two doses. However, such
a treatment plan, or one that considers any of the J doses at each administration
period would be infeasible in practice and would likely lead to treatment errors if
the treatment plans assigned to several patients were all different and impossible to
remember.
Furthermore, we have chosen to only consider reassignments when a new patient
is enrolled. This certainly is not the only benchmark at which we might consider
reassigning patients. For example, we might instead (or also) re-evaluate the data
collected so far each time a patient completes their follow-up, either by reaching ω
without a DLT or experiencing a DLT sometime before ω. Or we could re-evaluate
the data each time a patient completes a course, thereby allowing a course-by-course
evaluation for every patient. And if we truly wanted to optimize the treatment of
every patient in the study, it would seem most sensible to evaluate each patient after
every single administration. However, most of these alternate approaches are un-
realistic in practice as the frequency of the necessary computations would become
administratively impossible. On the opposite end of the spectrum, we could admin-
istratively set times, i.e. every three months, when we might consider reassignments
that have nothing to do with patient outcomes but makes the process of re-assignment
known before the trial begins. However, we feel our approach of re-evaluating assign-
ments when each new patient is enrolled is a good compromise between optimizing
the treatment of each patient as much as possible and maintaining a feasible level of
computation.
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3.2.6 Conduct of the Trial
We plan on enrolling a maximum of N patients in the trial, and each patient will
be followed for ω days after enrollment. The first patient is enrolled at study time
t = 0 and is assigned to the shortest schedule (k = 1) with the lowest dose (j = 1).
When patient i = 2, . . . , N is to be enrolled in the study at study time t, we perform
the following steps:
(1) Place each enrolled patient i
′
= 1, 2, . . . i−1 into one of two groups, either those
without DLT or those with DLT;
(2) For patients without DLT, record:
(i) Ci′ = 0, indicating no DLT
(ii) Ti′ = min{Wi′ ,i, ω}, where Wi′ ,i is the inter-patient time between patient
i′ and i;
(3) For patients with DLT, record:
(i) Ci′ = 1, indicating DLT
(ii) Ti′ = Yi′ , the patient time when a DLT occurred;
(4) For all enrolled patients, record si′ , the vector of times of each administration
received, and di′ , the vector of doses given at each administration;
(5) Use the information recorded from (2)-(4) above to compute the likelihood given
in Equation (3.3). Specifically, patients without DLT will contribute an amount
given in Equation (3.1) and patients with DLT will contribute an amount given
in Equation (3.2);
(6) Combine the likelihood with the prior distributions described in Section 3.2.4
to compute the posterior medians of φ and β;
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(7) Apply the methods described in Section 3.2.5 to determine whether to terminate
the trial, and if not, determine for each patient whether to assign a new dose
and/or schedule or terminate their treatment altogether;
(8) Determine the dose and schedule assignment for patient i using the methods
described in Section 3.2.5;
(9) Once all N patients have been enrolled, use all accumulated data to compute
final posterior estimates of the DLT rates of each dose and schedule combination




In the motivating azacitidine trial, there were J = 3 doses of interest: 8, 16 and
24 mg/m2, and K = 4 schedules with respective numbers of administrations m1 = 5,
m2 = 10, m3 = 15 and m4 = 20, for a total of 12 combinations. A course consists
of five daily consecutive administrations followed by 28 days of rest as described
in the example in Section 3.2.1, and schedule k consists of k consecutive courses.
Investigators would like to determine which of the 12 combinations has a DLT rate
close to η = 0.30. The maximum follow-up time for each patient is ω = 116 days. We
consider the dose-schedule combinations with DLT rates of η± 0.10 to be acceptable
choices of the MTC, since a small deviation from η is acceptable for the investigators
(Braun et al. 2007). A maximum of N = 60 patients will be enrolled.
We considered two skeletons that we feel would reflect those most commonly used
in practice. Skeleton 1 specifies the a priori MTC to exist at middle combinations
whereas Skeleton 2 specifies the highest combinations as the a priori MTC; the actual
values of the skeletons can be found in Table 3.2. For each skeleton, we used the
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Table 3.2: The two skeletons used in the simulation study. The boldfaced values correspond to
acceptable combinations.
Schedule
Skeleton Dose(mg/m2) 1 2 3 4
1 8 0.03 0.12 0.30 0.50
16 0.15 0.30 0.50 0.60
24 0.30 0.50 0.60 0.75
2 8 0.02 0.06 0.15 0.25
16 0.08 0.15 0.25 0.30
24 0.15 0.25 0.30 0.38
methods described in Section 2.5 to calculate the prior means. For Skeleton 1, this
leads to µ0 = −4.80, µ1 = −0.32, µγ = −0.818 and α = 1.73. The corresponding
values for Skeleton 2 were µ0 = −5.50, µ1 = −0.43, µγ = −0.822 and α = 1.72.
With either skeleton, the mode of the hazard function is around four days after
administration. For both skeletons, we calibrated the prior variances of our model
parameters through a process outlined in Section 3.5.2.
We examined our approach in 16 different scenarios that are summarized in Table
3.3. The true DLT rates of every combination of dose and schedule were not generated
by the model used in our methods but were instead created using an approach outlined
in Section 3.5.1.
Table 3.3 also contains three metrics that seek to measure how difficult finding the
MTC might be in each scenario. The first value, Nc, is the number of combinations
with DLT rates within 10 points of the target η, the second value, MSE, denotes
the mean sum-of-squared-errors for the fit of the linear model log[− log(1 − pdj)] =
β0 + exp(β1)dj, and the third value, SD, is the sample standard deviation of the 12
DLT rates. Thus, smaller values of Nc and SD would indicate greater difficulty of
finding the MTC and larger values of MSE would indicate that the linearity assumed
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Table 3.3: Summary of the 16 scenarios studied, including the actual DLT rates of each dose and
schedule combination and three metrics that measure the difficulty of identifying an MTC. Boldfaced
values indicate dose and schedule combinations with DLT rates within 10 points of the desired DLT
rate η = 0.30.
Schedule
Method Scenario Dose(mg/m2) 1 2 3 4 pd Nc MSE SD ξ
Independent 1 8 0.05 0.10 0.14 0.18 0.010 3 0.03 0.08 n/a
16 0.06 0.12 0.18 0.23 0.013
32 0.09 0.17 0.24 0.30 0.018
2 8 0.05 0.10 0.14 0.18 0.010 3 0.32 0.23 n/a
16 0.09 0.17 0.24 0.30 0.018
32 0.30 0.52 0.66 0.77 0.070
3 8 0.02 0.05 0.07 0.10 0.005 1 0.35 0.32 n/a
16 0.18 0.32 0.44 0.54 0.038
32 0.47 0.72 0.85 0.92 0.120
4 8 0.03 0.07 0.10 0.13 0.007 1 0.42 0.15 n/a
16 0.05 0.09 0.13 0.17 .0095
32 0.17 0.31 0.42 0.52 0.036
Gumbel 5 8 0.18 0.31 0.41 0.50 0.048 4 0.06 0.16 0.88
16 0.22 0.36 0.48 0.57 0.058
32 0.29 0.47 0.59 0.69 0.080
6 8 0.13 0.18 0.23 0.27 0.050 3 0.30 0.20 0.60
16 0.33 0.45 0.54 0.60 0.140
32 0.43 0.57 0.66 0.72 0.190
7 8 0.30 0.44 0.54 0.61 0.110 2 0.07 0.15 0.70
16 0.35 0.50 0.60 0.68 0.130
32 0.46 0.63 0.73 0.80 0.180
8 8 0.02 0.06 0.11 0.17 .0021 2 0.22 0.18 1.5
16 0.07 0.17 0.30 0.42 0.006
32 0.11 0.27 0.44 0.59 0.010
9 8 0.17 0.28 0.36 0.43 0.049 2 0.29 0.25 0.81
16 0.43 0.62 0.74 0.82 0.140
32 0.56 0.76 0.86 0.92 0.200
10 8 0.02 0.06 0.10 0.15 .0018 1 0.29 0.12 1.5
16 0.03 0.07 0.13 0.17 .0023
32 0.07 0.17 0.30 0.42 0.006
Frank 11 8 0.05 0.09 0.13 0.17 0.010 3 0.03 0.14 1.5
16 0.09 0.17 0.24 0.30 0.020
32 0.19 0.32 0.42 0.50 0.043
12 8 0.19 0.32 0.43 0.51 0.044 3 0.08 0.16 1.5
16 0.26 0.43 0.54 0.63 0.065
32 0.31 0.49 0.61 0.69 0.080
13 8 0.07 0.13 0.18 0.23 .0146 3 0.13 0.21 1.5
16 0.18 0.31 0.41 0.49 0.042
32 0.33 0.52 0.64 0.72 0.087
14 8 0.18 0.31 0.41 0.49 0.042 2 0.04 0.19 1.5
16 0.29 0.47 0.59 0.67 0.075
32 0.42 0.62 0.74 0.82 0.120
15 8 0.03 0.06 0.08 0.11 0.006 2 0.31 0.13 1.5
16 0.05 0.09 0.13 0.19 0.010
32 0.15 0.27 0.36 0.44 0.035
16 8 0.53 0.74 0.84 0.90 0.170 0 0.01 0.15 1.5
16 0.53 0.75 0.85 0.91 0.175
32 0.55 0.75 0.86 0.91 0.178
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in our model may be suspect and lead to a poorer ability of correctly identifying an
MTC.
We simulated patients to have exponentially distributed inter-arrival times with
a mean of two weeks, and we divided all the follow-up times by 10 to achieve better
numeric stability for our model. When a new patient is enrolled, an interim analysis is
performed in which a single chain of 6, 000 samples, after a burn-in of 4, 000 samples,
is drawn from the posterior distribution for each parameter. These posterior draws
are then used to determine the dose and schedule assigned to the new patient as
well as any dose and/or schedule reassignments for each currently enrolled patient
still being followed. We then simulate for each a binary indicator of DLT using the
method outlined in Section 3.5.1 depending upon the scenario examined. If a patient
is simulated to have a DLT, the time of the DLT is drawn uniformly from the interval
[4 + 24(k − 1), 4 + 24k] under their assigned schedule k, which also implies that all
possible DLTs occur by ω = 116 days. We did perform simulations of our design
using our assumed model to simulate DLTs and came to similar final conclusions,
and we have omitted those results for brevity.
We compared the performance of our approach that allows for patient reassign-
ment (Design A) with the traditional approach that does not allow for patient reas-
signment (Design B). We evaluated the performance of both approaches by comparing
the correct selection frequency at the end of the study, the mean proportion of patients
assigned to each dose-schedule combination and the mean proportion of patients who
experienced DLTs. We performed 1, 000 simulations in each scenario; our computer
code is available upon request.
3.3.2 Simulation Results
Table 3.4 contains a summary of the performance of Design A (with reassignment)
and Design B (without reassignment) in the 16 scenarios described in Table 3.3. For
each design, this summary is a series of eight columns. The first four columns describe
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the proportion of simulations in which the MTC selected at the end of the study
was not found, had a DLT rate more than 10 points below the desired DLT rate η
(column “L”), within 10 points of η (column “In”), or more than 10 points above
η (column “H”). The next three columns have a similar interpretation related to
the average percentage of dose-schedule assignments during the study. The eighth
column, labeled “DLT” is the average of the proportion of observed DLTs among the
1,000 simulations.
Overall, we are able to identify acceptable dose-schedule combinations at the end
of the study in a majority of simulations in the first 15 scenarios, whether or not
reassignment is used, as well as terminate the study early in scenario 16. These
results are not surprising, as the primary goal of reassignment is to optimize the
assignments of patients enrolled in the study, rather than improve the final decision
at the end of the study. Scenarios 4, 8, 9, and 10 have the lowest percentages of
identifying the MTC at an acceptable combination, which is partially explained by
the fact that these scenarios have only 1 or 2 acceptable combinations to choose
from. These scenarios also have some of the largest values of MSE, indicating that
the assumption of linearity in our model is suspect. Nonetheless, we emphasize that
all 15 scenarios have DLT rates that come from models that are different from our
assumed model, so that our approach works well even when the model is misspecified.
With regard to patient assignments during the study, we see that including reas-
signment leads to a higher proportion of patients assigned to acceptable combinations
than without reassignment. For example, Design A assigned 58% of the patients to
acceptable combinations in scenario 4, compared with only 29% for Design B, and the
corresponding percentages in scenario 10 are 53% and 26%, respectively. Moreover,
in all 15 scenarios, the average DLT rate when using reassignment is never more than
the average observed DLT rate without reassignment and is always close to the de-
sired DLT rate. Although Scenarios 7, 9 and 10 have 33%, 40% and 31% of patients,
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Table 3.4: Simulation results for Design A (with reassignment) and B (without reassignment), prior
standard deviation σ = 2 and Skeleton 2. For each design, there are four columns under “Selection”
list the percentage of simulations in which the MTC was not identified, was identified at combinations
with DLT rates below that desired, within that desired, and above that desired, respectively. Cor-
responding columns are listed under “Assignment” to describe the average percentage of patients
assigned to each combination. DLT = mean proportion of patients who experienced DLT. The
columns under “Reassignment” gives summary statistics on reassignment: Rp = average proportion
of patients receiving at least one reassignment during the study, Rm (Rsd) = mean (standard devi-
ation) of number of reassignments a patient received, R1 (Rn) = the average minimum (maximum)
number of reassignments a patient received.
Selection Assignment Reassignment
Scen Design None L In H L In H DLT Rp Rm Rsd R1 Rn
1 A 0 5 95 0 10 90 0 27 38 0.9 1 0 4.1
B 0 4 96 0 12 88 0 27
2 A 0 13 83 3 19 63 18 31 56 1.2 1.3 0 5.2
B 0 12 86 3 29 52 18 31
3 A 1 14 71 14 22 53 24 32 53 1 1.2 0 4.7
B 0 25 62 13 29 48 23 33
4 A 0 27 53 20 19 58 23 30 68 1.6 1.5 0 5.8
B 0 32 48 20 33 29 38 31
5 A 2 2 78 17 7 62 29 35 43 0.7 0.9 0 3.8
B 2 2 81 16 5 63 31 36
6 A 1 18 56 25 18 52 29 34 44 0.7 0.9 0 3.7
B 1 12 64 23 21 44 35 34
7 A 11 0 69 20 0 58 33 36 20 0.3 0.6 0 2.5
B 9 0 66 24 0 54 39 37
8 A 0 12 56 32 14 58 28 32 73 1.7 1.5 0 5.9
B 0 15 58 27 25 36 38 32
9 A 6 18 49 28 18 38 40 34 25 0.4 0.7 0 2.7
B 3 14 54 29 17 38 44 36
10 A 0 25 53 22 16 53 31 30 62 1.5 1.5 0 5.6
B 0 26 53 21 30 26 44 30
11 A 0 10 79 11 15 64 22 31 67 1.6 1.5 0 5.7
B 0 12 76 13 21 48 31 31
12 A 2 5 75 18 9 59 30 35 37 0.6 0.9 0 3.5
B 2 4 74 20 9 53 36 36
13 A 0 14 67 19 15 63 22 33 56 1.1 1.2 0 4.8
B 0 13 69 17 24 52 24 33
14 A 3 8 61 28 12 57 28 35 32 0.5 0.8 0 3.2
B 3 7 58 32 13 51 35 36
15 A 0 17 74 8 16 64 20 30 64 1.5 1.5 0 5.7
B 0 26 65 9 26 44 30 30
16 A 89 0 0 11 0 1 37 21 5 0.1 0.3 0 1.4
B 87 0 0 13 0 0 40 22
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respectively, assigned to toxic combinations, most of the combinations in Scenarios 7
and 9 are overly toxic, and exposing a higher proportion of patients to toxic combi-
nations in these scenarios seems unavoidable. Furthermore, in Scenario 10, all of the
assignments to toxic combinations were to combinations with DLT rates in the range
of 40%− 42%, and in Scenario 9, 25% of patients were assigned to combinations with
DLT rates between 40% and 45%. We also conducted simulations using the EWOC
distance measure described in Section 3.2.5, but due to space limitations, we omit
these results. We found that using the EWOC distance measure led to treating fewer
patients at overly toxic combinations in some scenarios, but this apparent increase in
safety came with a reduced ability of finding the MTC at the end of the trial.
The final five columns of Table 3.4 contain a summary of the number of reassign-
ments per patient that occurred in each of the 16 scenarios. Rates of reassignment
above 0.60 were seen in scenarios 4, 8, 10, 11, and 15. Although the explanation
for the high rate of reassignment is not immediately obvious, a partial explanation
is that acceptable combinations in these scenarios appear with longer schedules of
the highest dose, with even longer schedules then becoming overly toxic. In contrast,
Scenario 1 has a much lower rate of reassignment because that scenario had no overly
toxic combinations. We also see that less than two reassignments occurred per patient
on average in all the scenarios and just under six reassignments was the maximum
number of reassignments per patient on average in all scenarios.
We also examined the sensitivity of our design to the maximum sample size by
repeating our simulations using sample sizes of 50 and 70, the results of which are
summarized in Table 3.5. The results show that decreasing the sample size from 60
to 50 may result in a nontrivial loss is selecting correct combinations in Scenarios 4,
10 and 15. However, increasing the sample size from 60 to 70 only produces a minor
increase in the selection of correct combinations. Therefore, we selected a maximum
number of 60 patients for this study.
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Table 3.5: Simulation results for Design A with sample sizes of N = 50 and N = 70. For each
design, columns “Selection” gives the percentage of identifying three categories of combinations as
the MTC: unacceptable inefficacious combinations (“L”) ; acceptable combinations (“In”) and too
toxic combinations (“H”). For each design, columns “Assignment” gives the mean proportion of
patients assigned to the three categories, columns “DLT” give the mean proportion of patients who
experienced DLTs.
Design A with N = 50 Design A with N = 70
Selection Assignment Selection Assignment
Scen None L In H L In H DLT None L In H L In H DLT
1 0 6 94 0 11 89 0 27 0 5 95 0 9 91 0 27
2 0 17 79 4 21 58 21 31 0 11 86 2 17 66 17 31
3 0 16 66 17 24 49 26 33 0 12 73 15 20 56 23 32
4 0 32 45 24 20 54 26 30 0 25 57 18 18 61 21 30
5 2 3 78 18 8 58 32 35 1 2 82 15 7 66 26 34
6 1 19 55 25 18 50 31 35 1 12 64 22 16 55 27 34
7 9 0 66 25 0 55 38 37 9 0 73 18 0 61 32 35
8 0 16 55 30 16 54 30 33 0 12 57 31 14 61 25 32
9 4 17 48 31 20 34 43 36 3 16 53 28 19 39 40 35
10 0 28 50 22 18 48 34 30 0 26 54 20 17 54 29 30
11 0 14 74 12 16 60 24 31 0 10 80 11 15 65 20 31
12 3 5 68 25 10 53 35 36 2 4 78 17 9 62 28 35
13 1 15 64 20 15 59 25 33 0 13 70 16 14 66 20 32
14 3 9 54 34 12 54 31 36 1 7 61 31 11 61 26 35
15 0 22 68 10 18 58 23 30 0 18 75 7 15 66 18 30
16 83 0 0 17 0 1 42 24 89 0 0 11 0 1 34 19
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Figure 3.1: Comparison between Design A and B using Skeleton 1 and calibrated prior standard
deviation 2.
Recall that we found that using a value of σ = 2 for the prior variances of the
model parameters was insensitive to the skeleton used. To confirm this statement, we
do not present the results when using Skeleton 1 in a tabular format like that of Table
3.4. Instead, Figure 3.1 contains a visual summary of the percentage of simulations
in which the MTC was selected at an acceptable combination (left plot) and the
percentage of patients assigned to acceptable combinations (right plot) in each of the
15 scenarios. As we found in Table 3.4, we are able to identify the MTC well whether
or not reassignment is allowed, but that inclusion of reassignment greatly improves
the treatment assignment of patients enrolled in the study.
3.4 Discussion
In our methods, we reassigned the dose and/or schedule of each enrolled patient
only when a new patient was enrolled in order to optimize the treatment of each
patient but maintain a feasible level of computation. As a result, with an average
arrival of a new patient every 14 days relative to a follow-up of 116 days in our simula-
tions, we considered approximately no more than eight reassignments with each new
enrollment. In a study with much faster accrual, there would be many more possible
reassignments to consider at each new enrollment and many of the patients could have
several reassignments occurring during their treatment. Investigators may feel that
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this level of possible reassignment impractical, requiring a different rule for determin-
ing when reassignment is possible. An interesting area of research is to compare our
approach to other reassignment strategies to determine when fewer reassignments are
allowed, yet do not lead to significantly worsened operating characteristics.
Although we restricted the estimate of the MTC at the end of the trial to only exist
among dose-schedule regimens with dose constant within patient, our methods are
flexible enough to regimens with dose variations within-patient that ultimately might
provide a better MTC estimate since we are considering a richer set of candidate
strategies. In addition, we could consider multiple MTC estimates each of which
that are qualitatively different from each other. For example, we could consider two
completing MTC estimates, one with a few administrations of a higher dose and
another with many administrations of a lower dose. It is very possible that one
schedule may be more effective or easier to administer and these facts are not yet
part of our decision-making process. Certainly our methods can be generalized to
incorporate more information and further the process of discovering new drugs and
how to best administer them, and is an exciting avenue of research. Furthermore, our
methods belong to the family of dynamic treatment regimes (Murphy, 2002) and use
of additional patient information, such as a key biomarker for response or risk factors
for lack of response, might further the cause to “personalize” the dose and schedule
assigned to each patient. However, the major limiting factor for all these extensions
is the small sample size used in most early-phase clinical trials.
We introduce our design in the setting of dose-schedule finding studies, although
our methods could be easily applied to other settings. If the schedule were fixed
while the dose varied, our design would be similar to the TITE-CRM in which the
weight function would be determined by the functional form of the hazard function
of a single administration in our model. In Phase I/II studies, one can easily adapt
our method to the work of Yuan and Yin (2009) to model late-onset toxicity/efficacy
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and introduce intra-patient dose changes. Similar modifications could be made to
apply our approach to trials of combinations of two agents by specifying the hazard
function of the toxicity or efficacy after a single administration to be a function of
doses of both agents. However, the model that takes account of the joint distribution
of toxicity and efficacy as a function of possibly multiple doses is not immediately
obvious and should be carefully chosen. Lastly, in the motivating azacitidine trial,
the highest dose and longest schedule was reached with no evidence of unacceptable
toxicity and investigators decided to add more doses to the trial. The flexibility of our
model would allow one to adaptively estimate the DLT rates of other doses and/or
schedules to determine which, if any, might be added to the trial once it has begun.
3.5 Appendices
3.5.1 Algorithm for Simulating True DLT Rates
We let pdj denote the probability of DLT by ω after a single administration of dose
j = 1, 2, 3, and we let nj denote the number of administrations of dose j received.
Then, for a treatment schedule of n1, n2, and n3 administrations of doses 1, 2, and 3,
respectively, regardless of their order, we denote the actual probability of DLT by time
ω as Ptrue(d1, d2, d3, n1, n2, n3). In scenarios 1-4, we assume that all administrations
have independent effects (which is also the assumption used in our model), i.e.




in which qdj = 1 − pdj . In scenarios 5-10, we assume that all administrations have
correlated effects modeled via a Gumbel copula, i.e.






and is the same as Equation (3.4) when the correlation parameter ξ = 1. In scenarios
11-15, we assume that all administrations have correlated effects modeled via a Frank
copula, i.e.













and is the same as Equation(3.4) when ξ → 0.
The value of ξ used in each of scenarios 5-16 is shown in the last column of Table
3 of the manuscript and the actual values of pd1 , pd2 , and pd3 used in each of the
fifteen scenarios are shown in the column labeled “pd” in Table 3 of the manuscript.
Although Table 3 of the manuscript displays the DLT rates for each of the dose and
schedule combinations under study, the values in the column labeled “pd” can be
used to compute the actual DLT rates for patients who receive a reassignment that
does not fit one of these dose-schedule combinations. For example, suppose we have
a patient in scenario 1 who has been assigned to five administrations of 8 mg/m2
and five administrations of 16 mg/m2. This patient has a probability of DLT by ω of
1− (1− 0.010)5(1− 0.013)5 ≈ 0.11.
3.5.2 Calibration of Prior Variance
To achieve good operating characteristics, we first calibrated the prior standard
deviations via simulation using a maximum number of 60 patients. We let σ1, σ2
and σ3 have the same value σ to simplify the calibration process. The prior standard
deviation that performs best among σ = 1, 2, 5 would be used in the study. We
certainly could have examined more values of σ, but felt that choosing among these
three values was sufficient and any small deviations in performance with other possible
values for σ were outweighed by the increased amount of simulation time required.
The first row of Figure 3.2 shows how the prior variance impacts the proportion of
patients assigned to acceptable dose-schedule combinations in Design A using either
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Figure 3.2: Impact of prior standard deviation and skeletons on the MTC assignment for Design A.
skeleton 2 (upper left plot) or skeleton 1 (upper right plot). For both skeletons,
the design using σ = 5 performs worse than using σ = 1 or 2 in most of the 15
examined scenarios. However, from these two plots, it is not clear which among
between σ = 1 and σ = 2 would be preferred. Therefore, the bottom two plots
in Figure 3.2 attempt to assess the sensitivity of the results to the chosen skeleton
when using σ = 2 (lower left plot) and σ = 1 (lower right plot). From these two
plots, we see that there is greater variation in the results when using σ = 1 than
σ = 2. We also performed similar analyses for the proportion of simulations in which
acceptable dose-schedule combinations were selected at the end of the study, as well
as repeating our calibration with Design B (no reassignment), and found little change
in our conclusions. Therefore, we selected σ = 2 to be the prior standard deviation
used in the study. And since our design is not sensitive to the skeletons when σ = 2,
we have chosen to use Skeleton 2 in our study.
56
3.5.3 Illustration of Patient Reassignments
We selected the results from one of our simulations in Scenario 1 to visually display
how patient reassignments occur during a trial. To that end, we have a series of tables
that summarize patient assignments and reassignments after 10 patients have been
enrolled (Table 1), after 20 patients have been enrolled (Table 2), after 30 patients
have been enrolled (Table 3), etc., until the maximum sample size of N = 60 has
been enrolled (Table 6).
Recall that there are 3 dose levels and 4 nested schedules under investigation.
Each treatment course consists of 5 daily administrations followed by 28 days of
rest. In Tables 1-6, we let (a*b) denote a treatment assignment that corresponds
to b administrations at dose level a. Similarly, (a*b, c*d) denotes b administrations
at dose level a followed by d administrations at dose level c. For instance, (2*5,
3*5) denotes that the patient received five administrations of dose level 2 for five
consecutive days, had 28 days of rest, then received another five administrations of
dose level 3.
With regard to the information in each table, ID refers to the identification number
of the patient, “Time enrolled” is the study time when each patient is enrolled,
“Assign” contains the most recent assignment of the patient, “Reassign” indicates
the dose-schedule reassignment for each patient who received a reassignment, “DLT”
contains a indicator (1=yes; 0=no) if the patient experienced a DLT, “Follow-up” is
the time to DLT or the follow-up time if there has not been a DLT, and “Comp”
indicates whether the patient completed their follow-up (Y=yes; N=no).
We see in Table 1 that the first patient received the lowest dose-schedule combina-
tion (dose 1, schedule 1), and because no DLT had been observed when patient 2 was
enrolled, we initially assigned patient 2 to the combination of dose 2 and schedule
2. Similarly, we treated patient 3 at the combination of dose 3 and schedule 3 at
enrollment. When the fourth patient was enrolled, not only was that patient assigned
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Table 3.6: Summary of patient assignments and re-assignments when patient 11 is enrolled.
Time
ID Enrolled Assign Reassign DLT Follow-up Comp
1 0.0 1*5 n/a 0 116.0 Y
2 4.5 2*10 2*5, 3*5 1 112.2 Y
3 15.7 3*15 3*20 0 116.0 Y
4 48.0 3*20 n/a 1 59.4 Y
5 83.3 3*20 3*15 0 42.0 N
6 90.7 3*20 3*5, 2*15 0 34.6 N
7 97.3 3*20 3*15 0 28.0 N
8 103.6 3*20 3*15 0 21.7 N
9 109.0 3*20 3*15 0 16.3 N
10 117.8 2*20 2*5, 3*15 0 7.5 N
to the current best regimen (dose 3 and schedule 4), but the assignments of the first
three patients were re-examined for potential reassignment. As a result, the assign-
ment for patient 2 was escalated to 2*5, 3*15 and the assignment for patient 3 was
escalated from 3*15 to 3*20. Table 1 also demonstrates intra-patient de-escalation.
For instance, after we observed two DLTs for patients 2 and 4, the initial assignments
for patients 5-9 were changed to a dose-schedule combination with a lower DLT rate.
Finally, when patient 11 was enrolled, we saw that the initial assignment for patient
10 was escalated from 2*20 to 2*5, 3*15 because we only saw two DLTs by that time.
Table 2 also demonstrates how patient reassignments can be altered as more pa-
tients are enrolled. For example, in Table 1, patient 6, who had been originally
assigned to dose 3 and schedule 4 was reassigned to five administrations of dose 3 and
15 administrations of dose 2 by the time subject 11 was enrolled. Table 2 then shows
that patient 6 was reassigned again with a reduction to 10 administrations of dose 2
instead of the original 15 administrations, due to the DLT experienced by patient 10.
Similar conclusions can be reached from the information in Tables 3-6
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Table 3.7: Summary of patient assignments and re-assignments when patient 21 is enrolled.
Time
ID Enrolled Assign Reassign DLT Follow-up Comp
1 0.0 1*5 n/a 0 116.0 Y
2 4.5 2*5,3*5 n/a 1 112.2 Y
3 15.7 3*20 n/a 0 116.0 Y
4 48.0 3*20 n/a 1 59.4 Y
5 83.3 3*15 n/a 0 116.0 Y
6 90.7 3*5,2*15 3*5,2*10 0 116.0 Y
7 97.3 3*15 3*10, 1*5 0 116.0 Y
8 103.6 3*15 3*10, 1*5 0 116.0 Y
9 109.0 3*15 3*10, 1*5 0 116.0 Y
10 117.8 2*5,3*15 n/a 1 21.6 Y
11 125.3 3*15 3*5, 1*10, 3*5 0 116.0 Y
12 151.0 2*20 2*10, 3*10 0 116.0 Y
13 196.6 3*20 n/a 0 110.2 N
14 204.9 3*20 n/a 0 102.2 N
15 237.9 3*20 n/a 1 29.3 Y
16 239.2 3*20 n/a 0 67.9 N
17 247.4 3*20 n/a 0 59.7 N
18 278.6 3*20 n/a 0 28.5 N
19 282.7 3*20 n/a 0 24.4 N
20 294.2 3*20 n/a 0 12.9 N
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Table 3.8: Summary of patient assignments and re-assignments when patient 31 is enrolled.
Time
ID Enrolled Assign Reassign DLT Follow-up Comp
13 196.9 3*20 n/a 0 116.0 Y
14 204.9 3*20 n/a 0 116.0 Y
15 237.9 3*20 n/a 1 29.3 Y
16 239.2 3*20 n/a 0 116.0 Y
17 247.4 3*20 n/a 0 116.0 Y
18 278.6 3*20 n/a 1 75.9 Y
19 282.7 3*20 n/a 0 116.0 Y
20 294.2 3*20 n/a 0 116.0 Y
21 302.5 3*20 n/a 0 116.0 Y
22 307.1 3*20 n/a 1 71.8 Y
23 314.6 3*20 n/a 1 76.0 Y
24 339.2 3*20 3*15 0 116.0 Y
25 340.0 3*20 n/a 1 18.2 Y
26 377.7 3*20 3*5, 2*10 0 82.2 N
27 391.7 3*15 3*5, 2*15 1 27.8 Y
28 410.6 3*15 n/a 1 27.5 Y
29 458.4 2*20 n/a 0 1.5 N
30 458.9 2*20 n/a 0 1.0 N
Table 3.9: Summary of patient assignments and re-assignments when patient 41 is enrolled.
Time
ID Enrolled Assign Reassign DLT Follow-up Comp
26 377.7 3*5, 2*10 n/a 0 116.0 Y
27 391.7 3*5, 2*15 n/a 1 27.8 Y
28 410.6 3*15 n/a 1 27.5 Y
29 458.4 2*20 2*5, 3*10 1 35.1 Y
30 458.9 2*20 2*5,3*5,1*5,2*5 0 116.0 Y
31 459.9 2*20 2*5,3*5,1*5,2*5 0 116.0 Y
32 468.0 2*20 2*17, 3*3 0 116.0 Y
33 500.6 2*20 2*10, 3*5, 2*5 0 91.1 N
34 520.2 2*20 2*10, 3*10 0 71.5 N
35 522.5 2*20 2*8, 3*2, 2*5,3*5 0 69.2 N
36 532.0 2*20 2*5,3*5,2*5,3*5 0 59.7 N
37 538.4 2*20 2*5, 3*10 0 53.3 N
38 540.6 2*20 2*5, 3*10 0 51.1 N
39 553.5 3*10 3*5,2*5,3*5 0 38.2 N
40 570.2 3*15 3*5, 2*15 0 21.5 N
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Table 3.10: Summary of patient assignments and re-assignments when patient 51 is enrolled.
Time
ID Enrolled Assign Reassign DLT Follow-up Comp
33 500.6 2*10, 3*5, 2*5 n/a 0 116.0 Y
34 520.2 2*10, 3*10 n/a 0 116.0 Y
35 522.5 2*8, 3*2, 2*5,3*5 n/a 0 116.0 Y
36 532.0 2*5,3*5,2*5,3*5 n/a 0 116.0 Y
37 538.4 2*5, 3*10 2*5,3*5,2*5,3*5 0 116.0 Y
38 540.6 2*5, 3*10 2*5,3*5,2*5,3*5 1 89.9 Y
39 553.5 3*5,2*5,3*5 3*5,2*10,3*5 0 116.0 Y
40 570.2 3*5, 2*15 3*5,2*10,3*5 0 116.0 Y
41 591.7 3*15 3*10,2*5,3*5 0 85.0 N
42 591.8 3*15 3*10,2*5,3*5 0 84.9 N
43 601.6 3*15 3*10,2*5,3*5 0 75.1 N
44 605.9 3*15 3*10,2*5,3*5 0 70.8 N
45 634.2 3*15 3*15 0 42.5 N
46 655.5 3*15 n/a 0 21.2 N
47 664.4 3*15 n/a 0 12.3 N
48 668.1 3*15 n/a 0 8.6 N
49 668.6 3*15 n/a 0 8.1 N
50 673.4 3*15 n/a 0 3.3 N
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Table 3.11: Summary of patient assignments and re-assignments at the end of the study.
Time
ID Enrolled Assign Reassign DLT Follow-up Comp
41 591.7 3*10,2*5,3*5 n/a 0 116.0 Y
42 591.8 3*10,2*5,3*5 n/a 0 116.0 Y
43 601.6 3*10,2*5,3*5 n/a 0 116.0 Y
44 605.9 3*10,2*5,3*5 n/a 0 116.0 Y
45 634.2 3*15 n/a 0 116.0 Y
46 655.5 3*15 3*20 0 116.0 Y
47 664.4 3*15 n/a 0 116.0 Y
48 668.1 3*15 n/a 0 116.0 Y
49 668.6 3*15 3*15,1*5 0 116.0 Y
50 673.4 3*15 3*15,1*5 0 116.0 Y
51 676.7 3*15 n/a 1 18.1 Y
52 712.7 3*15 3*20 1 28.0 Y
53 714.1 3*15 3*20 0 116.0 Y
54 728.3 3*15 3*20 1 113.5 Y
55 744.6 3*15 3*20 1 86.7 Y
56 761.0 3*20 n/a 0 116.0 Y
57 761.1 3*20 n/a 0 116.0 Y
58 766.6 3*20 n/a 0 116.0 Y
59 769.9 3*20 n/a 0 116.0 Y
60 773.7 3*20 n/a 0 116.0 Y
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CHAPTER IV
A Bayesian Phase I/II Adaptive Design to
Simultaneously Optimize Dose and Schedule
Assignments by Modeling Toxicity and Efficacy as
Time-to-event Outcomes
4.1 Introduction
Most published methodology of Phase I or Phase I/II oncology trials focuses on
dose finding. In such studies, the investigators usually propose a dosing schedule prior
to the onset of a study and aim to identify an optimal dose in terms of toxicity and/or
efficacy under that schedule. The traditional 3+3 method or more recent model-
based methods, for example, the Continual Reassessment Method (CRM) proposed
by O’Quigley, Pepe, and Fisher (1990), are suitable for Phase I dose-finding studies.
Alternatively, many Phase I/II dose-finding designs based on the joint outcomes of
both toxicity and efficacy have been proposed. For example, see Braun (2002), Thall
and Russell (1998), Thall and Cook (2004) and Yuan and Ying (2009).
It is obvious that such dose-finding studies might not perform well when the pre-
determined dosing schedule is not chosen correctly and leads to the conclusion that all
the doses under investigation are either too toxic or too inefficacious. To address this
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issue, Braun et al. (2007) first proposed a dose- and schedule-finding design based
on the schedule-finding design of Braun et al. (2004) by defining separate hazard
functions for modeling time to a dose-limiting toxicity (DLT) for each dose. Liu
and Braun (2009) also generalized the work of Braun et al. (2004) by incorporating
smoother hazard functions. Although the cited work focuses on nested schedules,
Li et al. (2008) explored a Phase I/II adaptive design for finding an optimal dose
and schedule combination when schedules are not nested by using a Bayesian isotonic
transformation and binary patient outcomes.
However, there are several design issues the current methods in dose- and schedule-
finding studies fail to address. First, most published methods for dose-schedule finding
were created with solely toxicity as the outcome while the extension to where toxicity
and efficacy outcomes are considered jointly is not obvious. Second, even though Li et
al. (2008) do model toxicity and efficacy outcomes jointly for dose-schedule finding,
their design requires binary patient outcomes and patients have to be fully followed
before a new cohort of patients can be enrolled. However, the efficacy outcome usually
requires a relatively long period of follow-up, resulting in an undesirably long trial.
In addition, a trial using such a design would be suspended to enrollment during fast
accrual because incoming patients would have to wait until all the enrolled patients
complete their follow-up. Third, intra-patient dose modifications during a trial are
common in practice, often a result of unexpected outcomes that may benefit from a
reduced dose. Also, in newer oncology trials involving molecularly targeted agents
with low toxicity rates, the investigator might intentionally apply intra-patient dose
escalation to those patients who do not achieve a certain efficacy endpoint after a
first treatment cycle in order to have better clinical outcomes (Cutsem et al. 2012).
However, there has not been any systematic approach to accommodate intra-patient
dose modification in Phase I/II studies.
To address the above design issues, we first define separate hazard functions for
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time to toxicity and time to response after a patient receives a single administra-
tion. We extend these hazards to accommodate multiple administrations using a
non-mixture cure rate model and derive the marginal survival function for toxic-
ity and efficacy outcomes. A copula model is then assumed for the joint survival
function. We further define acceptable and optimal dose-schedule treatment regimes
using the criteria based on both estimated toxicity and response rates. Patient ac-
crual, data monitoring, early stopping and outcome-adaptive regimen assignment are
done continually throughout the trial under a Bayesian formulation. We introduce
two case studies that motivate our work in Section 4.2 for both nested and non-nested
schedules. We describe our method and model in Section 4.3 and introduce the trial
conduct in Section 4.4. We illustrate our method and algorithm in our motivating
trials in Sections 4.5 and 4.6 for nested and non-nested schedules, respectively. We
conclude with a discussion in Section 4.7.
4.2 Case Studies
4.2.1 Nested Schedule - Treating acute myelogenous leukemia (AML)
and myelodysplastic syndrome (MDS)
Azacitidine is a DNA methyltransferase inhibitor with activity in myeloid disease.
It was hypothesized by de Lima, et al. (2010) that low-dose azacitidine administered
after transplant would reduce recurrence rates of AML and MDS. Instead of con-
sidering the long-term event-free survival, a short term efficacy endpoint in an early
phase trial is complete response (CR). The investigators investigated combinations
of five daily doses: 8, 16 and 32 mg/m2 and 4 schedules: 1, 2, 3, or 4 cycles, each
with five days of drug and 23 days of rest. A limited number of azacitidine cycles
were administered because of concerns of sustained myelosuppression as well as pos-
sible induction of graft-versus-host disease(GVHD). Toxicity is defined as any of the
following adverse events occurring within 116 days from the start of the first cycle:
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1) National Cancer Institute Grade 3 or higher renal, hepatic, cardiac, pulmonary, or
neurologic toxicity; 2) Grade 3/5 acute GVHD; 3) serious infection; 4) severe hema-
tologic toxicity/graft failure. Response is defined as the event of CR, that is, < 6%
bone marrow blasts and evidence of donor chimerism (> 80%) by DNA microsatellite
polymorphism analysis. Development of drug-related Grade 3 or 4 organ toxicity or
severe infection led to azacitidine discontinuation. Azacitidine was also discontinued
if platelet count dropped to < 10, 000/mm3, with 50% dose reduction if platelet count
dropped to < 20, 000/mm3.
4.2.2 Non-nested Schedule - Treating metastatic colorectal cancer
Irinotecan was the first drug to improve survival beyond that achieved with
standard first-line treatment of colorectal cancer. Combining irinotecan with oral
capecitabine is an interesting alternative in view of the practicability of the treat-
ment. However, there is no consensus on the dose and schedule of irinotecan in
presence of standard treatment of oral capecitabine (Borner et al. 2008). Two non-
nested schedules are suggested: weekly irinotecan on days 1, 8, 15, 22, 29 or tri-weekly
irinotecan on day 1 and days 22 every six weeks for six cycles. Doses for the weekly
schedule are 35, 70 and 90 mg/m2 and doses for the tri-weekly schedule are 180, 240
and 300 mg/m2. Hence, there are a total of six dose-schedule treatment regimes
under investigation. Toxicity is defined as any of the Grade 3/4 toxicity according
to the National Cancer Institute. Response is defined as any of a complete response
(CR), partial response (PR) or minor response (at least a 25% decrease in tumor size)
reviewed by an independent radiology panel. There is an intra-patient dose reduc-
tion rule stating that doses should be reduced by 25% in the subsequent treatment





A typical dose-schedule-finding trial involving nested schedules aims to identify an
optimal treatment regimen within a J×K matrix consisting of J doses and K nested
schedules. Patients receive administrations under schedule k, k = 1, . . . , K at times
s(k) = (s1, s2, . . . , sm(k)) where s
(1) ⊂ s(2) ⊂ . . . ⊂ s(K) and m(1) < m(2) < . . . < m(K).
In the azacitidine trial, there are J = 3 doses and K = 4 nested schedules. A single
course of treatment, includes 5 administrations on first 5 consecutive days and the
administration times are denoted by s(1) = (0, 1, 2, 3, 4). Patients receive the second
treatment course after 28 days of rest, hence s(2) = (0, 1, 2, 3, 4, 28, 29, 30, 31, 32) =
(s(1), s(1) + 28) and so on. Let dj denote the per-administration dose, j = 1, . . . , J ,
then sk and dj denote the possible dose and schedule regimes to be initially assigned
to a patient and dj ∈ (8, 16, 32) mg/m2. However, due to possible intra-patient dose
modification, the patient may not receive the same dose dj for each administration.
Hence, patient i may receive different doses di = (di,1, . . . , di,mi) at administration
times si = (si,1, . . . , si,mi) where mi is the number of administrations patient i has
received.
Non-nested schedules, in contrast, are qualitatively different from each other and
do not consist of the same treatment course. In the irinotecan trial, K = 2 non-nested
schedules are under investigation. The administration times are denoted as s10 =
(0, 7, 14, 21, 28) for a single treatment cycle using the weekly schedule and s20 = (0, 21)
for a single treatment cycle using the tri-weekly schedule. Since the investigator plans
six cycles, the administration times for the tri-weekly schedule are s(2) = (0, 21, 42,






















Contrary to nested schedules, the set of doses under investigation for each schedule
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could be different. Let d1j denote the per-administration dose j for the weekly schedule
and d2j denote for the corresponding dose for the tri-weekly schedule, where j =
1, . . . , J , the total number of doses considered for each schedule. In our example, J
=3, d1j ∈ (35, 70, 90) mg/m2 and d2j ∈ (180, 240, 300) mg/m2. Again, even though the
dose and schedule regimen sk and dkj , k = 1, . . . , K, might be assigned to patient i
initially, she might experience dose modification for later treatment cycles. We still
use di and si to denote the dose and schedule combination one actually receives.
Regardless of either nested or non-nested schedules, a patient will be followed for
a maximum duration of ωT and ωE for evaluating whether the patient experiences a
toxicity or response, respectively. The values ωT and ωE are often determined by the
clinician and also known as the duration of the evaluation window for toxicity and
efficacy.
4.3.2 Marginal Model for Time-to-Event After a Single Administration
Let c = T or R be an indicator for the toxicity outcome (T) or efficacy outcome
(R). We expect the hazard function for either outcome after a single administration to
increase with time to certain time and then attenuate as we want to mimic the biologic
of the agent (Liu and Braun, 2009). We define the hazard function at time ν for event
c as gc(ν|θc, φc) = θcf(ν|φc) where θc is a positive scale parameter and f(ν|φc) is a
probability density function with a certain restriction on the parameter φc such that
the mode of f(·) exists. Let F (ν|φc) denote the cumulative density function of f(·).
The above model corresponds to the non-mixture cure rate model proposed by Chen,
Ibrahim, and Sinha (1999) since the survival function S(ν|θc, φc) = exp[−θcF (ν|φc)] is
not proper and S(∞|θc, φc) = exp(−θc) > 0 is the cure probability, i.e., the proportion
of the population who would never experience toxicity (c=T) or response (c=R).
Therefore, 1− exp(−θc) is the toxicity or response rate after a single administration
of a dose with infinite follow-up.
Chen et al. (1999) also suggested modeling covariate effects through θc to maintain
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a proportional hazards structure. To make the concept distinct, we denote θi,l,c as the
cure parameter associated with dose di,l for administration l to patient i. Since θi,l,c >
0, we model it as a function of the dose di,l for administration l through log(θi,l,c) =
β0,c + exp(β1,c)di,l, where the slope is positive because it is reasonable to assume
that toxicity and response rates increase with dose. However, if the monotonicity
assumption is not valid, one option is to use a second order polynomial. We choose





where φc = (αc, γc) and we require αc > 1 so
the mode of the density exists. Therefore, the respective hazard and survival functions
for patient i after administration l at dose di,j are g(νi,l|βc,φc) = θi,l,cf(νi,l|φc) and
S(νi,l|βc,φc) = exp[−θi,l,cF (νi,l|φc)], in which βc = (β0,c, β1,c). More details about
the model assumptions have been presented in Chapter III.
4.3.3 Marginal Model for Time-to-Event After Multiple Administrations
Assume patient i receives mi administrations at administration times (si,1, si,2,
. . ., si,mi) and the respective per-administration doses are (di,1, di,2, . . ., di,mi). By
employing a competing risks approach, we assume that there is a latent event time
Yi,l after each administration, and the patient time when patient i experiences an
event is min(Yi,1 + si,1, . . . , Yi,mi + si,mi). At patient time ti, the survival function for
Yi is given by
φ(ti|β,φ, si,di) = P (Yi > ti) = P (Yi,1 > yi,1, . . . , Yi,mi > yi,mi)
where yi,l = ti − si,l.
However, we do not assume Yi,1, . . . , Yi,mi are independent since they are from
the same patient and we may want to consider within-patient correlation, which we
did not take into account in Chapter III. We introduce a frailty variable wi > 0,
conditional on which Yi,1, . . . , Yi,mi are independent. Specifically, after consider-
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ing bivariate outcomes (c=T or R), the hazard and survival functions after admin-
istration l of multiple administrations are g(νi,l|βc,φc, wi) = wiθi,l,cf(νi,l|φc) and
S(νi,l|βc,φc, wi) = exp[−wiθi,l,cF (νi,l|φc)]. While there are several choices for the






















Using the Laplace transform of wi, considering bivariate outcomes (c =T, R) and
following the derivation of Chen, Ibrahim, and Sinha (2002), one can derive the
marginal survival function for the patient event time Yi,c as
ϕc(tc,i|βc,φc, λc, sc,i,dc,i) =
∞∫
0








where log(θi,l,c) = β0,c + exp(β1,c)di,l. Note that the number of administrations mi,c
could be different when considering different outcomes, since toxicity and response
could occur at different times. λc > 0 is a correlation parameter that quantifies the
amount of within-patient correlation and λc = 1 implies that there is no within-patient
correlation.
The toxicity and response rate πc(j, k) for a dose-schedule combination (j, k)
within the duration of the respective evaluation windows ωc is then given by πc(j, k) =
1− ϕc(ωc) where the parameters are omitted for brevity.
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4.3.4 Joint Model, Likelihood and Posterior
In order to take into account the possible correlation between times to toxic-
ity and efficacy, we construct the joint bivariate survival function by employing
an Archimedean copula model, which specifies a well-defined relationship between
marginal and joint distributions. We adopt the Clayton copula model (Clayton 1978;
Yuan and Ying 2009) because it is simple and easy to interpret. Specifically, the
bivariate survival function is given by
S(tT,i, tE,i|ζ,βT ,φT , λT ,βE,φE, λE, si,di)
=
[
ϕT (tT,i|βT ,φT , λT , sT,i,dT,i)−ζ + ϕE(tE,i|βE,φE, λE, sE,i,dE,i)−ζ − 1
]−1/ζ
(4.2)
Note that ζ > 0 is a correlation parameter that defines the amount of correlation
between times to toxicity and response. There is no correlation when ζ = 0 since
Kendall’s tau that measures bivariate association is equal to ζ/(2 + ζ).
For toxicity, define patient time YT,i = min(YT,i, UT,i) and δT,i = I(YT,i ≤ UT,i),
where UT,i denotes the censoring time and I(·) is the indicator function. Hence, we
observe toxicity for patient i if Ci = 1. Similarly, YE,i and δE,i are defined for efficacy.
Since interim analyses are performed whenever a new cohort is enrolled, by the time
cohort n+ 1 is enrolled, we denote the number of patients currently in the study as n
and for each enrolled patient, we observe yT,i, δT,i, yE,i, δE,i, si and di, where si and
di, as we defined previously, are the respective time and dose for each administration
patient i has received, i = 1, . . . , n. Note Ui = min(Wi,n+1, ω), where Wi,n+1 is the
inter-patient time between patient i and n + 1. If n = N , the maximum number
of patients for the study, then define Wi,n+1 as the time between patient i and the
end of the study. It is reasonable to assume random censoring since Wi,n+1 is usually
independent of the DLT time and ω is a fixed value. Based on the above information
and (4.2), the likelihood of the data Di = (yT,i, δT,i, yE,i, δE,i, si,di) for patient i is
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given by











2S(yT,i, yE,i|τ , si,di)/∂yT,i∂yE,i,
L2 = −∂S(yT,i, yE,i|τ , si,di)/∂yT,i,
L3 = −∂S(yT,i, yE,i|τ , si,di)/∂yE,i,
L4 = S(yT,i, yE,i|τ , si,di).
Let τ = (ζ,βT ,φT , λT ,βE,φE, λE). After determining the prior distribution p(τ ),
the posterior distribution of τ based on D = {Di : i = 1, ..., n} is




We can compute posterior quantities via adaptive Markov Chain Monte Carlo (MCMC)
methods (Rosenthal 2007). Those posterior quantities will be used to identify the
dose-schedule assignment for a new cohort of patients.
4.3.5 Establishing Prior Distributions
For the parameters βc and λc (c=T or R), we assign independent Gaussian distri-
butions with prior mean and prior variance (µ0, σ
2
0,c) for β0,c, (µ1,c, σ
2
1,c) for β1,c and
(µ3,c, σ
2
2,c) for log(λc). The means are elicited from the investigators who are asked to
provide the “skeleton” P , the a priori estimates of the toxicity and response rates for
all dose-schedule combinations, in which element (j, k), denoted Pjk, corresponds to
the toxicity rate or response rate of dose j and schedule k treatment regimen. We then
fit the linear regression model log(− log[1−Pjk,c]) = λc log(mk,c)+λcb0,c+λc exp(b1,c)dj
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(dj is replaced by d
k
j for non-nested schedules) derived from Equation (4.1) and use
the ordinary least square estimates b̂0,c, b̂1,c and λ̂c as the respective values for µ0,c,
µ1,c and µ2,c.
For the parameters of the Weibull density in the hazard, φc = (αc, γc), we adopt
the same approach outlined in Chapter III and in Liu and Braun (2009). Specifically,
we keep αc fixed to maintain a parsimonious model and limit the number of parameters
to estimate. In addition, we assign a Gaussian prior distribution for γc with mean
µγ,c and variance σ
2
γ,c.
For the correlation parameter ζ for the bivariate time-to-event outcomes, we re-
parameterize ζ = (ζs)
2 and assign a Gaussian distribution with mean µζ and variance
σ2ζ to ζs. We choose µζ to be 0.
As in Chapter III, we recommend calibrating the prior variances through simula-
tions using a few different skeletons and prior variances. The prior variance that is
the most insensitive to skeletons and leads to the best operating characteristics will
be used for a real trial.
4.4 Trial conduct
4.4.1 Decision Criteria
We adopt the decision criteria in terms of posterior probabilities given D at any
interim analysis in the trial similar to Thall and Russell (1998) and many other
Phase I/II trial designs. Given upper probability cutoffs pT and pE, we consider a
dose-schedule combination, denoted by (j,k), to be a regimen with acceptably low
toxicity rate if
P{πT (j, k) < πT |D} > pT (4.3)
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and to be a regimen with acceptably high response rate if
P{πE(j, k) > πE|D} > pE, (4.4)
where πT and πE are a fixed upper limit on toxicity rate and lower limit on response
rate respectively. A dose-schedule regimen is acceptable if it satisfies both (4.3) and
(4.4). We denote the set of acceptable strategies based on D to be A(D). In order
to have good operating characteristics for the design, the values of cut-off values pT
and pE should be carefully calibrated via simulations prior to the onset of a trial.
The optimal regimen was defined to be the one in A(D) that maximizes the
posterior response probability in (4.4), a rule proposed by Thall and Russell (1998).
However, the above criteria might not work well when πE(j, k) is much above pT for
several dose-schedule regime because the probabilities in (4.4) would be very close to
1 and cause some numerical problems, since there would be more than one optimal
treatment regime. Hence, we further propose the following additional criteria for
accepting a dose-schedule regimen:
π̂T (j, k) < πT + ∆T (4.5)
for toxicity and
π̂E(j, k) > πE −∆E (4.6)
for efficacy. π̂T (j, k) and π̂E(j, k) are posterior mean of the toxicity and response
rates; ∆T and ∆E are cut-off values and usually assumed to be equal. We further
re-define the set A(D) to be those strategies that satisfy (4.3) to (4.6).
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4.4.2 Trial Conduct for Nested Schedules
We plan on enrolling a maximum of N patients in the trial in V cohorts with
n0 patients per cohort, and each patient will be followed for ωT and ωE days after
enrollment for toxicity and efficacy respectively. The first cohort of patients are
enrolled at study time t = 0 and assigned to the shortest schedule (k = 1) with the
lowest dose (j = 1) or the dose-schedule regimen specified by the clinician. When
cohort i = 2, . . . , V is to be enrolled in the study at study time t, we perform the
following steps:
(a) Record the observed data Di′ for each enrolled patient i
′
= 1, 2, . . . , (i− 1)n0;
(b) Compute the likelihood and draw samples from posterior distributions;
(c) Similar to Thall and Cook (2004), dose-schedule combination (j, k) ∈ A(D) if
(j, k) satisfies (4.3) to (4.6), or if (j, k) is the lowest untried regimen above the
starting regimen and it satisfies (4.3) and (4.5);
(d) If A(D) 6= φ, then the next cohort is treated at the optimal regimen in A(D),
subject to the constraint that no untried dose or schedule can be skipped when
escalating;
(e) If A(D) = φ, then consider the following conditions:
(i) If (4.3) or (4.5) is not satisfied, then the trial is terminated and no dose-
schedule regimen is selected;
(ii) if it is the first time that (4.3) and (4.5) are satisfied but not for (4.4)
or (4.6), then treat the next cohort at the regimen that maximizes the
estimated response rate subject to the same no-skipping rule in (c); Oth-
erwise if it is not the first time, then terminate the trial and no regimen is
selected.
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(f) If all N patients have been enrolled and the trial is not stopped early, then
select the combination in A(DN) that maximizes the estimated response rate
(we use its posterior mean) in (4.6).
4.4.3 Trial Conduct for Non-nested Schedules
In contrast with nested schedules, the ordering in terms of either toxicity or re-
sponse rates of two dose-schedule regime with two different non-nested schedules are
usually unknown. Hence, in order to have good operating characteristics, some as-
pects of the algorithm used for nested schedules need to be modified even though
the rest remains the same. Firstly, the lowest dose-schedule combination is unknown
and hence the regimen to be assigned to the first cohort has to be specified by the
clinician. Secondly, we introduce adaptive randomization when assigning the a dose-
schedule regimen to the next cohort rather than assigning the optimal regimen to the
next cohort in the steps (d) and (e)(ii) with probability 1. The randomization is done
as follows:
(i) Compute the estimated response rates π̂E(j, k) for all dose-schedule regime in
A(D);
(ii) For each schedule k = 1, . . . , K, find the jopt(k) = argmax
j=1,2,...,J
π̂E(j, k);








opt(k′) = 0 if jopt(k′) = φ.
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4.5 Application - The Azacitidine Trial
4.5.1 Simulation Design
In the motivating azacitidine trial, the clinicians specified J = 3 doses of interest:
8, 16 and 24 mg/m2, and K = 4 nested schedules, for a total of 12 combinations. A
course consists of five daily consecutive administrations followed by 28 days of rest
as described in the example in Section 4.3.1, and schedule k consists of k consecutive
courses. The maximum follow-up time for each patient is ωT = ωE = 116 days. A
maximum of N = 60 patients will be enrolled with the cohort size 3. The algorithm
was implemented with pT = 0.4, pE = 0.1, πT = 0.35 ,πE = 0.35 and ∆T = ∆E = 0.05
starting at the lowest dose and schedule (dose 1 and schedule 1). Investigators would
like to determine which of the 12 combinations is the optimal treatment regimen in
terms of both toxicity and efficacy.
We asked the investigator to provide the estimates of the toxicity and response
rates for each of the 12 dose-schedule combinations. The skeleton specifies the middle
combinations to be the optimal regimes. The actual values of the skeleton can be
found in Table 4.2. We used the methods described in Section 4.3.5 to calculate
the prior means that are shown in Table 4.1. We calibrated the prior variances
of our model parameters through a process outlined in Chapter III. We assumed
the variances for all the prior distributions are equal and tried three different prior
standard deviations, 1, 2 and 4. We selected prior standard deviation(SD)=2 for the
trial.
We examined our approach in eight different scenarios that are summarized in Ta-
ble 4.2 in which the true toxicity and response rates are denoted by a pair (πT , πE).
The true toxicity and response rates of every combination of dose and schedule were
generated by the model used in our methods with the frailty following the positive
stable distribution defined in Section 4.3.3. We simulated patients to have exponen-
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tially distributed inter-arrival times with a mean of two weeks, and we divided all the
follow-up times by 10 to achieve better numerical stability for our model. When a new
cohort is enrolled, an interim analysis is performed in which a single chain of 6, 000
samples, after a burn-in of 4, 000 samples, is drawn from the posterior distribution
for each parameter. These posterior draws are then used to determine the dose and
schedule assigned to the new patient. We evaluated the performance of our approach
by comparing the correct selection frequency at the end of the study and the mean
proportion of patients assigned to each dose-schedule combination. We performed
500 simulations in each scenario; our computer code is available upon request.
4.5.2 Simulation Results
Table 4.3 contains a summary of the performance of our design in the eight sce-
narios described in Table 4.2. Columns 3-6 describe the proportion of simulations in
which each of the dose-schedule combination is selected as the optimal regimen at the
end of the study. Column 7 describes the proportion of simulations that are stopped
early. The next three columns have a similar interpretation related to the average
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Table 4.2: The true toxicity and response rates and the skeleton used in the simulation study. The
boldfaced values correspond to acceptable combinations.
Schedule (πT , πE)
Sc. Dose 1 2 3 4
1 1 (0.54,0.41) (0.71,0.55) (0.80,0.63) (0.86,0.69)
2 (0.56,0.43) (0.73,0.57) (0.82,0.66) (0.88,0.71)
3 (0.59,0.45) (0.75,0.59) (0.84,0.68) (0.89,0.73)
2 1 (0.03,0.02) (0.05,0.04) (0.07,0.05) (0.09,0.06)
2 (0.03,0.02) (0.06,0.04) (0.09,0.06) (0.11,0.08)
3 (0.04,0.03) (0.08,0.05) (0.11,0.07) (0.14,0.09)
3 1 (0.06,0.18) (0.11,0.26) (0.16,0.32) (0.19,0.36)
2 (0.11,0.26) (0.19,0.36) (0.27,0.44) (0.33,0.49)
3 (0.19,0.36) (0.32,0.49) (0.43,0.58) (0.51,0.64)
4 1 (0.05,0.10) (0.07,0.18) (0.1,0.24) (0.11,0.27)
2 (0.08,0.14) (0.12,0.26) (0.16,0.34) (0.18,0.39)
3 (0.12,0.21) (0.20,0.36) (0.25,0.48) (0.29,0.53)
5 1 (0.14,0.28) (0.20,0.40) (0.25,0.48) (0.29,0.55)
2 (0.28,0.30) (0.39,0.43) (0.46,0.52) (0.52,0.58)
3 (0.50,0.33) (0.65,0.46) (0.74,0.55) (0.80,0.62)
6 1 (0.13,0.14) (0.21,0.20) (0.28,0.24) (0.33,0.27)
2 (0.20,0.28) (0.32,0.39) (0.41,0.46) (0.48,0.49)
3 (0.30,0.50) (0.46,0.65) (0.58,0.74) (0.65,0.77)
7 1 (0.26,0.54) (0.38,0.59) (0.46,0.62) (0.51,0.64)
2 (0.34,0.55) (0.48,0.60) (0.57,0.63) (0.62,0.65)
3 (0.44,0.55) (0.60,0.60) (0.69,0.63) (0.74,0.65)
8 1 (0.05,0.07) (0.10,0.13) (0.13,0.18) (0.16,0.21)
2 (0.10,0.20) (0.18,0.33) (0.24,0.44) (0.29,0.51)
3 (0.18,0.47) (0.32,0.70) (0.42,0.82) (0.48,0.88)
Skeleton 1 (0.13,0.18) (0.21,0.28) (0.28,0.33) (0.32,0.35)
2 (0.14,0.28) (0.30,0.33) (0.34,0.40) (0.38,0.44)
3 (0.30,0.33) (0.35,0.44) (0.40,0.48) (0.45,0.53)
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percentage of dose-schedule assignments during the study.
Overall, we are able to identify acceptable dose-schedule combinations at the end
of the study in a majority of simulations and stop the trial early if there is no regimen
that is both safe and efficacious. In Scenario 1, all the regimes are overly toxic
because all of their toxicity rates are above the upper limit πT . We terminated the
trial in 100% of the simulations. In Scenario 2, none of the regimes is efficacious
enough because all of the response rates are below the lower limit πE. The trial
was terminated in all the simulations. In Scenarios 3-8, we are able to identify the
acceptable and the optimal regimes with high probability. For example, in Scenario 5,
the combinations of dose 1 and one of schedules 2-4 are acceptable treatment regimes.
But the combinations (dose 1, schedule 3) and (dose 1, schedule 4) have much higher
response rates but still relatively low toxicity rates; hence they could be considered as
the optimal combinations in this scenario. We select them 15% and 65% respectively
at the end of trial. Scenario 6 might be the most difficult for dose-schedule finding
among the scenarios we explored, because there are only two acceptable dose-schedule
treatment regimes and their toxicity rates are very close to πT but their response rates
are not much higher than πE. The trial was stopped early in 10% of the simulations
due to the difficulty in finding the correct treatment regimes. Even in this scenario,
we selected the acceptable regimes in 50% of the simulations. In Scenario 7, the trial
was stopped with the probability 13%. This is because most of the combinations are
overly toxic and only two are acceptable ones.
In terms of patient assignment, we find that a high percentage of patients were
treated at the acceptable dose-schedule regimes. In Scenario 1, we treated 20% of the
total patients before the trial was stopped early due to safety and most of the enrolled
patients were treated at the lowest dose and schedule combination. In Scenario 2,
we enrolled 35% of the total patients before the trial was terminated due to futility
and most of treated patients were on the highest dose-schedule regimen. In Scenarios
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Table 4.3: Simulation results for the azacitidine trial with sample size of N = 60. Columns “%
Sel” gives the percentage of identifying each dose-schedule combination as the optimal treatment
regimen. Column “ None” gives the percentage of simulations that were stopped early. Columns “%
Pat” gives the mean proportion of patients assigned to each dose-schedule regimen. The boldfaced
values correspond to acceptable combinations.
% Sel % Pat
Schedule Schedule
Scenario Dose 1 2 3 4 None 1 2 3 4
1 1 0 0 0 0 100 11 2 1 3
2 0 0 0 0 2 1 0 1
3 0 0 0 0 0 0 0 0
2 1 0 0 0 0 100 0 0 0 6
2 0 0 0 0 0 0 0 5
3 0 0 0 0 0 0 0 24
3 1 0 0 1 10 1 0 1 1 16
2 0 4 17 33 1 2 6 31
3 8 17 6 2 3 8 9 22
4 1 0 0 0 0 1 0 0 0 6
2 0 0 0 5 0 0 0 10
3 0 1 6 87 0 1 2 80
5 1 2 6 15 65 2 2 5 8 51
2 3 3 2 1 4 6 6 8
3 1 0 0 0 3 2 3 3
6 1 0 3 5 11 10 1 3 4 17
2 14 14 4 0 8 10 6 9
3 36 2 0 0 19 9 4 6
7 1 52 7 1 0 13 29 14 6 9
2 19 1 0 0 14 5 3 3
3 6 0 0 0 5 2 1 1
8 1 0 0 0 1 0 0 0 0 8
2 0 2 6 12 0 2 3 17
3 26 39 9 5 9 19 14 27
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3-8, we were able to treat many patients at the acceptable regimes: 66%, 93%, 64%,
29%, 57% and 48% respectively. At the same time, we did not expose many patients
to overly toxic combinations. For example, if we consider the regimes with toxicity
rate over πT + 0.05 as overly toxic, the percentage of overdosed patients are 20%, 0%,
22%, 0%, 25%, 34%, 31% and 27% in Scenarios 1-8 respectively.
We calibrated the variances of the prior distributions via simulations. Table 4.4
summarizes the simulation results using prior SD = 1 and 4. We note that the
results are quite similar for prior SD =1 and 2. However, the results from using prior
SD=4 differ greatly from others because we note more simulations were stopped early.
Hence, we chose prior SD= 2 because our design selected the correct regimen slightly
more often in Scenario 5 however quite similar in other scenarios.
We examined the sensitivity of our design to model misspecification in Table 4.5.
Our model assumes a positive stable frailty, so we evaluated our method when the
frailty actually follows an Inverse Gaussian distribution with mean 1 and variance
adjusted to make the toxicity and response rates for each scenarios match Table
4.3. Overall, we find that our design’s ability to identify and assign the correct dose-
schedule regimes is not compromised, although we might assign slightly more patients
to toxic treatment regimes.
We also examined the sensitivity of our design to the maximum sample size by
repeating our simulations using sample sizes of 48 and 72, the results of which are
summarized in Table 4.6. The results show that decreasing the sample size from 60
to 48 may result in a nontrivial loss is selecting and assigning correct combinations.
However, increasing the sample size from 60 to 72 only produces a minor increase
in the selection and assignment of correct combinations. Therefore, we selected a
maximum number of 60 patients for this study.
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Table 4.4: Simulation results for the azacitidine trial with sample size of N = 60 using different
prior variances. Columns “% Sel” gives the percentage of identifying each dose-schedule combination
as the optimal treatment regimen. Column “ None” gives the percentage of simulations that were
stopped early. Columns “% Pat” gives the mean proportion of patients assigned to each dose-schedule
regimen. The boldfaced values correspond to acceptable combinations.
% Sel % Pat
Schedule Schedule
Prior Sd Scenario Dose 1 2 3 4 None 1 2 3 4
1 1 1 0.2 0 0 0 99.8 16 4 2 2
2 0 0 0 0 2 1 0 1
3 0 0 0 0 0 0 0 0
2 1 0 0 0 0 100 0 0 0 6
2 0 0 0 0 0 0 0 6
3 0 0 0 0 0 0 0 25
5 1 1 9 18 59 1 1 4 9 50
2 2 6 3 1 3 7 7 9
3 1 0 0 0 4 3 3 1
6 1 0 1 5 14 8 0 2 4 19
2 13 15 3 0 6 10 8 10
3 37 3 0 0 20 10 5 4
7 1 59 16 4 1 2 24 20 10 13
2 16 1 0 0 12 6 3 4
3 1 0 0 0 4 2 1 1
4 1 1 0.2 0 0 0 99.8 10 2 0 3
2 0 0 0 0 1 1 0 1
3 0 0 0 0 0 0 0 0
2 1 0 0 0 0 100 0 0 0 6
2 0 0 0 0 0 0 0 6
3 0 0 0 0 0 1 1 21
5 1 3 7 12 63 4 3 6 7 48
2 3 2 2 1 4 5 5 8
3 1 0 0 0 4 2 2 4
6 1 0 5 3 9 12 3 5 4 14
2 18 13 3 1 9 10 5 7
3 31 4 0 0 20 9 4 7
7 1 37 6 1 1 27 26 10 4 7
2 16 0 0 0 13 4 2 3
3 12 0 0 0 9 2 1 1
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Table 4.5: Simulation results for the azacitidine trial under model mis-specification with sample size
of N = 60. Columns “% Sel” gives the percentage of identifying each dose-schedule combination
as the optimal treatment regimen. Column “ None” gives the percentage of simulations that were
stopped early. Columns “% Pat” gives the mean proportion of patients assigned to each dose-schedule
regimen. The boldfaced values correspond to acceptable combinations.
% Sel % Pat
Schedule Schedule
Scenario Dose 1 2 3 4 None 1 2 3 4
1 1 0.2 0 0 0 99.8 13 3 2 2
2 0 0 0 0 2 1 0 0
3 0 0 0 0 0 0 0 0
2 1 0 0 0 0 100 0 0 0 5
2 0 0 0 0 0 0 0 6
3 0 0 0 0 0 0 0 23
3 1 0 0 0 6 2 0 0 0 12
2 0 2 16 33 0 1 5 31
3 6 21 11 4 3 9 11 28
4 1 0 0 0 0 2 0 0 0 5
2 0 0 0 3 0 0 0 9
3 0 0 5 89 0 1 2 82
5 1 0 6 10 78 2 1 4 7 56
2 1 2 1 0 4 6 6 6
3 0 0 0 0 4 2 3 2
6 1 0 2 3 11 5 1 3 3 15
2 11 19 5 1 6 11 9 10
3 40 2 0 0 23 9 4 6
7 1 54 12 2 1 7 28 16 6 9
2 18 1 0 0 15 5 3 4
3 4 0 0 0 5 2 1 1
8 1 0 0 0 0 1 0 0 0 7
2 0 0 3 17 0 1 2 18
3 20 38 15 6 7 20 14 32
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Table 4.6: Simulation results for the azacitidine trial under with sample size of N = 48 and 72.
Columns “% Sel” gives the percentage of identifying each dose-schedule combination as the optimal
treatment regimen. Column “ None” gives the percentage of simulations that were stopped early.
Columns “% Pat” gives the mean proportion of patients assigned to each dose-schedule regimen.
The boldfaced values correspond to acceptable combinations.
% Sel % Pat
Schedule Schedule
Prior Sd Scenario Dose 1 2 3 4 None 1 2 3 4
48 1 1 0 0 0 0 100 12 2 2 2
2 0 0 0 0 2 0 0 0
3 0 0 0 0 0 0 0 0
2 1 0 0 0 0.2 99.8 0 0 0 6
2 0 0 0 0 0 0 0 6
3 0 0 0 0 0 0 0 24
5 1 2 11 14 57 2 2 5 6 35
2 3 3 4 1 3 5 6 8
3 2 0 0 0 3 2 2 3
7 1 49 12 2 1 10 21 11 5 9
2 17 1 0 0 11 5 2 4
3 6 0 0 0 5 2 1 1
8 1 0 0 0 0 1 0 0 0 7
2 0 3 6 13 0 1 3 14
3 22 35 12 7 6 14 10 25
72 1 1 0 0 0 0 100 12 2 1 3
2 0 0 0 0 2 1 0 1
3 0 0 0 0 0 0 0 0
2 1 0 0 0 0 100 0 0 0 6
2 0 0 0 0 0 0 0 5
3 0 0 0 0 0 0 0 23
5 1 1 6 13 73 1 2 5 9 67
2 1 3 2 0 4 6 6 9
3 0 0 0 0 3 3 3 3
7 1 58 8 0 1 11 40 17 7 9
2 19 0 0 0 19 5 3 3
3 4 0 0 0 6 2 1 1
8 1 0 0 0 0 0 0 0 0 7
2 0 1 5 17 0 2 3 21
3 32 35 8 2 13 27 16 30
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4.6 Application - The Irinotecan Trial
4.6.1 Simulation Design
In the motivating irinotecan trial, clinicians specified J = 3 doses for each of
the two non-nested schedules, for a total of 6 combinations. Specifically, the doses
are 35, 70 and 90 mg/m2 for weekly schedule and 180, 240 and 300 mg/m2 for tri-
weekly schedule. The maximum follow-up time for each patient is ωT = ωE = 420
days. A maximum of N = 72 patients will be enrolled in cohorts of three patients.
The algorithm was implemented with pT = 0.4, pE = 0.1, πT = 0.35 and πE =
0.35. (dose 1, schedule 1) is assigned to the first cohort and (dose 1, schedule 2)
is assigned to the second cohort, because the ordering of toxicity or response rate
of the two dose-schedule regimes is unknown. Our algorithm begins with the third
cohort. Investigators would like to determine which of the six combinations is the
optimal treatment regimen for both toxicity and efficacy. The prior means as well
prior variances of model parameters are shown in Table 4.7 and the skeleton can be
found in Table 4.8 and Table 4.9. We tried three different prior SDs (1, 2 and 4) and
selected prior SD = 1 for the trial.
We examined our approach in seven different scenarios that are summarized in
Table 4.8. The true toxicity and response rates are also generated from our assumed
model. We simulated patients to have exponentially distributed inter-arrival times
with a mean of four weeks. The rest of the simulation designs are the same as those
in Section 4.5.
4.6.2 Simulation Results
Overall, our design performs well in all of the seven scenarios according to the
results summarized in Table 4.8. In Scenarios 1-2, the trial was stopped early in 100%
and 99.6% of the simulations due to toxicity and futility respectively. We assigned 15%
and 29% of the patients before the trial was terminated on average. In Scenarios 3-8,
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we are able to select the acceptable regimes with probabilities 100%, 100%, 57%, 80%
and 65%. For patient assignment, we note that most of patients were treated at
acceptable dose-schedule regimes.
We examined the sensitivity of our design to the maximum sample size by re-
peating our simulations using sample sizes of 60, the results of which are summarized
in Table 4.9. The results show that decreasing the sample size from 72 to 60 may
result in a nontrivial loss is selecting and assigning correct combinations. Therefore,
we selected a maximum number of 60 patients for this study. We also examined the
sensitivity of our design for prior variance and model misspecification. Our conclusion
is similar to that in the azacitidine trial and we have omitted these results for brevity.
4.7 Discussion
In our algorithm, we define the acceptable dose-schedule regimes to be the set
A(D) that satisfies both toxicity and efficacy constraints and we further define the
optimal regimen to be the regimen in A(D) with the highest estimated response rate.
More generally, the optimal dose-schedule regimen could be based on maximizing
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Table 4.8: Simulation results for the itinotecan trial with sample size of N = 72. Columns “%
Sel” gives the percentage of identifying each dose-schedule combination as the optimal treatment
regimen. Column “ None” gives the percentage of simulations that were stopped early. Columns “%
Pat” gives the mean proportion of patients assigned to each dose-schedule regimen. (π0T ,π
0
E) denotes
the skeleton used in the trial. The boldfaced values correspond to acceptable combinations.
Weekly Schedule Tri-weekly Schedule
Sc. Dose 1 Dose 2 Dose 3 Dose 1 Dose 2 Dose 3 None
(π0T ,π
0
E) (.07,.15) (.15,.40) (.33,.50) (.05,.15) (.19,.40) (.32,.50)
1 (πT ,πE) (.55,.27) (.67,.36) (.74,.43) (.51,.28) (.72,.46) (.9,.67)
% Sel 0 0 0 0 0 0 100
% Pat 10 1 0 15 1 0
2 (πT ,πE) (.07,.08) (.09,.09) (.11,.11) (.06,.05) (.1,.07) (.18,.09)
% Sel 0 0 0 0 0 0.4 99.6
% Pat 4 4 15 4 4 8
3 (πT ,πE) (.07,.27) (.09,.36) (.11,.43) (.06,.28) (.1,.46) (.18,.67)
% Sel 0 0 10 0 0 90 0
% Pat 4 4 36 9 5 41
4 (πT ,πE) (.11,.5) (.15,.56) (.18,.59) (.1,.28) (.17,.35) (.29,.43)
% Sel 0 0 98 0 0 2 0
% Pat 5 5 46 9 8 27
5 (πT ,πE) (.25,.51) (.4,.63) (.51,.71) (.49,.52) (.83,.74) (.99,.91)
% Sel 57 10.4 0 1 0 0 31
% Pat 47 12 1 16 1 0
6 (πT ,πE) (.37,.51) (.45,.63) (.5,.71) (.26,.52) (.38,.74) (.53,.91)
% Sel 10 5 0 43 27 4 11
% Pat 21 7 4 34 19 8
7 (πT ,πE) (.2,.29) (.26,.4) (.31,.47) (.21,.32) (.33,.52) (.5,.76)
% Sel 3 9 28 6 37 15 3
% Pat 12 12 24 17 19 15
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Table 4.9: Simulation results for the itinotecan trial with sample size of N = 60. Columns “%
Sel” gives the percentage of identifying each dose-schedule combination as the optimal treatment
regimen. Column “ None” gives the percentage of simulations that were stopped early. Columns “%
Pat” gives the mean proportion of patients assigned to each dose-schedule regimen. π0T ,π
0
E denotes
the skeleton used in the trial. The boldfaced values correspond to acceptable combinations.
Weekly Schedule Tri-weekly Schedule
Sc. Dose 1 Dose 2 Dose 3 Dose 1 Dose 2 Dose 3 None
(π0T ,π
0
E) (.07,.15) (.15,.40) (.33,.50) (.05,.15) (.19,.40) (.32,.50)
1 (πT ,πE) (.55,.27) (.67,.36) (.74,.43) (.51,.28) (.72,.46) (.9,.67)
% Sel 0 0 0 0 0 0 100
% Pat 12 0 0 17 2 0
2 (πT ,πE) (.07,.08) (.09,.09) (.11,.11) (.06,.05) (.1,.07) (.18,.09)
% Sel 0 0 0.4 0 0 0.4 99.2
% Pat 5 5 18 10 5 10
3 (πT ,πE) (.07,.27) (.09,.36) (.11,.43) (.06,.28) (.1,.46) (.18,.67)
% Sel 0 0 17 0 1 83 0
% Pat 5 5 35 10 6 38
4 (πT ,πE) (.11,.5) (.15,.56) (.18,.59) (.1,.28) (.17,.35) (.29,.43)
% Sel 0 1 95 0 0 4 0
% Pat 6 6 41 11 9 26
5 (πT ,πE) (.25,.51) (.4,.63) (.51,.71) (.49,.52) (.83,.74) (.99,.91)
% Sel 52 13 1 2 0 0 33
% Pat 44 12 2 20 2 0
6 (πT ,πE) (.37,.51) (.45,.63) (.5,.71) (.26,.52) (.38,.74) (.53,.91)
% Sel 7 2 1 42 31 4 13
% Pat 22 8 4 32 18 9
7 (πT ,πE) (.2,.29) (.26,.4) (.31,.47) (.21,.32) (.33,.52) (.5,.76)
% Sel 5 11 31 5 30 15 3
% Pat 14 13 22 18 18 14
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the posterior estimate of a utility function that explicitly incorporates the trade-off
between toxicity and efficacy. Obviously, the utility function should decrease with the
toxicity rate and increase with the response rate. For instance, a possible choice is
the odds ratio between the response and toxicity rate. However, the odds ratio might
not work for all drugs, since the critical aspect of using a utility function is that it
should reflect clinical knowledge and background. Hence, it is important to interact
with clinicians regarding the details on toxicity and efficacy trade-off.
Another possible extension of our current method is to implement dose and/or
schedule re-assignment to our design. While dose-schedule regimen is assigned to the
next cohort adaptively during the trial, a patient, once being assigned, is assumed to
receive the same initially assigned regimen (except when the dose is reduced due to
the dose reduction rule) even though it might turn out to be a sub-optimal regimen
later in the trial. However, the benefit of introducing re-assignment in a Phase I/II
trial is not directly clear. Furthermore, the potential benefit might really depend on
what utility function and re-assignment rule are used in the trial.
We used a relatively parsimonious model in our design because the sample size is
usually small in early phase trials and the overall model fit is not the primary goal
for a dose and/or schedule finding study. However, if the investigator is concerned
about the model assumptions, we could certainly adopt a more complex model. For
example, one could model the correlation parameter λc as a function of dose to make
the model more flexible. A strong assumption made in our method is that the toxicity
and response rates increase with dose, which is reasonable for azacitidine, irinotecan
and many other cytotoxic agents. However, for some newer cytostatic agents, the
response rates might not necessarily increase with dose. In such situations, one might
use a second order polynomial to model the relationship between log(θc) and dose.
Another assumption in our model is that we can observe the exact event time for
both toxicity and efficacy outcomes. However, in practice, one might only observe
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them in a certain interval, for instance, it might be sensible to evaluate the efficacy
outcomes every month instead of continually. Our model could be easily extended to
accommodate such interval censored data, in which the intervals are pre-specified by
the clinician.
Another interesting area of research is to develop methods to accommodate patient
dropout. Patients might have such severe side effects that they might drop out from
the study, or worse, they might die. In such situations, if the response has not yet
occurred, the response would most likely be informatively censored. However, if a
response has occurred without toxicity, patients would still receive treatment and be
under follow-up. Hence, toxicity could possibly censor efficacy outcome, but not vise
versa. Possible future work is to adopt a semi-competing risks model to solve the




In this dissertation we relax the assumption of a fixed prior variance in the tra-
ditional CRM for a Phase I dose-finding design and propose three systematic ap-
proaches to adaptively calibrate the prior variance continually throughout the trial.
Our approaches have the ability to perform better than the traditional CRM using a
constant prior variance as well as methods that calibrate the prior variance only at
the beginning of the trial.
We have contributed to the existing literature on the design of Phase I dose- and
schedule-finding studies by first expanding the schedule-finding model used by Liu
and Braun (2009) to incorporate variations in dose and have then incorporated an
algorithm for assessing whether or not currently enrolled patients should have their
assigned dose and/or schedule changed to one with an estimated DLT rate closer to
that desired. We modeled the per-administration dose as a covariate through the cure
parameter of the hazard function for a single administration in the framework of the
cure rate model, which is particularly attractive as a significant number of patients
would not have DLTs from a new agent. While the functional form of the hazard
function of a single administration can be chosen to reflect the background of a specific
study, another major advantage of our method lies in the flexibility to model any
sequence of dose and administration combinations. Furthermore, we have proposed
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an algorithm to optimize the intra-patient dose-schedule reassignment in addition to
the conventional method for inter-patient optimization. Simulations indicate that
our design identifies correct dose and schedule combinations as well as the traditional
method that does not allow for intra-patient doses-schedule reassignments, but with
a larger number of patients assigned to those combinations.
Finally, we generalize the Phase I dose-schedule-finding design to allow for mod-
eling both toxicity and efficacy in Phase I/II dose-schedule-finding clinical trials. We
propose marginal time-to-toxicity and time-to-response models based on the cure rate
model for multiple administrations with the per-administration dose as a covariate
through the cure parameter of the hazard function for each single administration.
The bivariate model is then constructed using a copula function. Furthermore, we
describe both toxicity and efficacy acceptability criteria for selecting the optimal dose-
schedule regimen as well as for stopping the trial early in case of a overly toxic or
inefficacious trial.
We have discussed the future work for each project in the corresponding discus-
sion section for each chapter. However, one important next step common to all three
projects is to write, validate, document and publish robust, efficient and open-source
routines to implement each method, using uniform syntax and a parsimonious set of
control parameters. This will generate a simulation platform that can be used by any
member of the statistical community to compare the operating characteristics of vari-
ous trial designs or to modify our source code to tailor to their specific studies. These
routines will be maintained in a single R package and posted on CRAN. Furthermore,
we are also planning to develop user-friendly software or a web-based application to
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